Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,31545497,IC50,"The in vitro experiments suggested that ticagrelor inhibited CYP3A4 activity, with IC50 and inhibitor constant (Ki) values of 68.74 and 26.47 µM, respectively; prasugrel also inhibited CYP3A4, activity with IC50 and Ki values of 16.24 and 10.84 µM, respectively.",Evaluation of cytochrome P450 3A4‑mediated drug‑drug interaction potential between P2Y12 inhibitors and statins. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31545497/),μM,68.74,219,DB08816,Ticagrelor
,31545497,inhibitor constant (Ki),"The in vitro experiments suggested that ticagrelor inhibited CYP3A4 activity, with IC50 and inhibitor constant (Ki) values of 68.74 and 26.47 µM, respectively; prasugrel also inhibited CYP3A4, activity with IC50 and Ki values of 16.24 and 10.84 µM, respectively.",Evaluation of cytochrome P450 3A4‑mediated drug‑drug interaction potential between P2Y12 inhibitors and statins. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31545497/),μM,26.47,220,DB08816,Ticagrelor
,31545497,IC50,"The in vitro experiments suggested that ticagrelor inhibited CYP3A4 activity, with IC50 and inhibitor constant (Ki) values of 68.74 and 26.47 µM, respectively; prasugrel also inhibited CYP3A4, activity with IC50 and Ki values of 16.24 and 10.84 µM, respectively.",Evaluation of cytochrome P450 3A4‑mediated drug‑drug interaction potential between P2Y12 inhibitors and statins. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31545497/),μM,16.24,221,DB08816,Ticagrelor
,31545497,Ki,"The in vitro experiments suggested that ticagrelor inhibited CYP3A4 activity, with IC50 and inhibitor constant (Ki) values of 68.74 and 26.47 µM, respectively; prasugrel also inhibited CYP3A4, activity with IC50 and Ki values of 16.24 and 10.84 µM, respectively.",Evaluation of cytochrome P450 3A4‑mediated drug‑drug interaction potential between P2Y12 inhibitors and statins. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31545497/),μM,10.84,222,DB08816,Ticagrelor
>,30715279,m/z,"Ticagrelor and IS were detected in the multiple reaction monitoring mode at m/z transition 523.4 > 127.0 and 530.4 > 127.0, respectively.",Development and Validation of Simple LC-MS-MS Assay for the Quantitative Determination of Ticagrelor in Human Plasma: its Application to a Bioequivalence Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30715279/),,523.4,2195,DB08816,Ticagrelor
>,30715279,m/z,"Ticagrelor and IS were detected in the multiple reaction monitoring mode at m/z transition 523.4 > 127.0 and 530.4 > 127.0, respectively.",Development and Validation of Simple LC-MS-MS Assay for the Quantitative Determination of Ticagrelor in Human Plasma: its Application to a Bioequivalence Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30715279/),,127.0,2196,DB08816,Ticagrelor
>,30715279,m/z,"Ticagrelor and IS were detected in the multiple reaction monitoring mode at m/z transition 523.4 > 127.0 and 530.4 > 127.0, respectively.",Development and Validation of Simple LC-MS-MS Assay for the Quantitative Determination of Ticagrelor in Human Plasma: its Application to a Bioequivalence Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30715279/),,530.4,2197,DB08816,Ticagrelor
>,30715279,m/z,"Ticagrelor and IS were detected in the multiple reaction monitoring mode at m/z transition 523.4 > 127.0 and 530.4 > 127.0, respectively.",Development and Validation of Simple LC-MS-MS Assay for the Quantitative Determination of Ticagrelor in Human Plasma: its Application to a Bioequivalence Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30715279/),,127.0,2198,DB08816,Ticagrelor
,30715279,flow rate,"Chromatographic separation was performed on a Phenomenex Luna® C18 column using a mobile phase consisting of 0.1% formic acid in water-acetonitrile (20:80, v/v) at a flow rate of 0.2 mL/min.",Development and Validation of Simple LC-MS-MS Assay for the Quantitative Determination of Ticagrelor in Human Plasma: its Application to a Bioequivalence Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30715279/),[ml] / [min],0.2,2199,DB08816,Ticagrelor
,30715279,retention times,"The retention times of ticagrelor and IS were 1.03 min and 1.02 min, respectively.",Development and Validation of Simple LC-MS-MS Assay for the Quantitative Determination of Ticagrelor in Human Plasma: its Application to a Bioequivalence Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30715279/),min,1.03,2200,DB08816,Ticagrelor
,30715279,retention times,"The retention times of ticagrelor and IS were 1.03 min and 1.02 min, respectively.",Development and Validation of Simple LC-MS-MS Assay for the Quantitative Determination of Ticagrelor in Human Plasma: its Application to a Bioequivalence Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30715279/),min,1.02,2201,DB08816,Ticagrelor
,32915088,AUCinf,"Pharmacokinetic exposure (AUCinf = 1472 ng·h/mL) associated with administration of 10 mg/kg of dronedarone increased significantly, with delayed T max in the group that received ticagrelor-pretreatment when compared to the dronedarone only group (AUCinf = 723 ng·h/mL).",Pharmacokinetic interaction between dronedarone and ticagrelor following oral administration in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32915088/),[h·ng] / [ml],1472,5817,DB08816,Ticagrelor
,32915088,AUCinf,"Pharmacokinetic exposure (AUCinf = 1472 ng·h/mL) associated with administration of 10 mg/kg of dronedarone increased significantly, with delayed T max in the group that received ticagrelor-pretreatment when compared to the dronedarone only group (AUCinf = 723 ng·h/mL).",Pharmacokinetic interaction between dronedarone and ticagrelor following oral administration in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32915088/),[h·ng] / [ml],723,5818,DB08816,Ticagrelor
,32915088,AUCinf,"In addition, pharmacokinetic exposure (AUCinf = 2391 ng·h/mL) associated with administration of 10 mg/kg of ticagrelor increased significantly, with increased K el (0.31 h-1) and decreased V z/F (14.6 L/kg) in the dronedarone-pretreatment group when compared to the ticagrelor only group (AUCinf = 1616 ng·h/mL; K el = 0.21 h-1; V z/F = 31.3 L/kg).",Pharmacokinetic interaction between dronedarone and ticagrelor following oral administration in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32915088/),[h·ng] / [ml],2391,5819,DB08816,Ticagrelor
,32915088,K el,"In addition, pharmacokinetic exposure (AUCinf = 2391 ng·h/mL) associated with administration of 10 mg/kg of ticagrelor increased significantly, with increased K el (0.31 h-1) and decreased V z/F (14.6 L/kg) in the dronedarone-pretreatment group when compared to the ticagrelor only group (AUCinf = 1616 ng·h/mL; K el = 0.21 h-1; V z/F = 31.3 L/kg).",Pharmacokinetic interaction between dronedarone and ticagrelor following oral administration in rats. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32915088/),1/[h],0.31,5820,DB08816,Ticagrelor
,32915088,V z/F,"In addition, pharmacokinetic exposure (AUCinf = 2391 ng·h/mL) associated with administration of 10 mg/kg of ticagrelor increased significantly, with increased K el (0.31 h-1) and decreased V z/F (14.6 L/kg) in the dronedarone-pretreatment group when compared to the ticagrelor only group (AUCinf = 1616 ng·h/mL; K el = 0.21 h-1; V z/F = 31.3 L/kg).",Pharmacokinetic interaction between dronedarone and ticagrelor following oral administration in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32915088/),[l] / [kg],14.6,5821,DB08816,Ticagrelor
,32915088,AUCinf,"In addition, pharmacokinetic exposure (AUCinf = 2391 ng·h/mL) associated with administration of 10 mg/kg of ticagrelor increased significantly, with increased K el (0.31 h-1) and decreased V z/F (14.6 L/kg) in the dronedarone-pretreatment group when compared to the ticagrelor only group (AUCinf = 1616 ng·h/mL; K el = 0.21 h-1; V z/F = 31.3 L/kg).",Pharmacokinetic interaction between dronedarone and ticagrelor following oral administration in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32915088/),[h·ng] / [ml],1616,5822,DB08816,Ticagrelor
,32915088,K el,"In addition, pharmacokinetic exposure (AUCinf = 2391 ng·h/mL) associated with administration of 10 mg/kg of ticagrelor increased significantly, with increased K el (0.31 h-1) and decreased V z/F (14.6 L/kg) in the dronedarone-pretreatment group when compared to the ticagrelor only group (AUCinf = 1616 ng·h/mL; K el = 0.21 h-1; V z/F = 31.3 L/kg).",Pharmacokinetic interaction between dronedarone and ticagrelor following oral administration in rats. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32915088/),1/[h],0.21,5823,DB08816,Ticagrelor
,32915088,V z/F,"In addition, pharmacokinetic exposure (AUCinf = 2391 ng·h/mL) associated with administration of 10 mg/kg of ticagrelor increased significantly, with increased K el (0.31 h-1) and decreased V z/F (14.6 L/kg) in the dronedarone-pretreatment group when compared to the ticagrelor only group (AUCinf = 1616 ng·h/mL; K el = 0.21 h-1; V z/F = 31.3 L/kg).",Pharmacokinetic interaction between dronedarone and ticagrelor following oral administration in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32915088/),[l] / [kg],31.3,5824,DB08816,Ticagrelor
,30689800,reactivity index,"On Day 45 after AMI the antiplatelet effect of ticagrelor was evaluated with the VASP assay and Multiplate, and there were no significant differences in platelet inhibition between patients on reduced vs. standard MD [VASP: 10.4 (5.6-22.2) vs. 14.1 (9.4-22.1) platelet reactivity index; P = 0.30; Multiplate: 30.0 (24.0-39.0) vs. 26.5 (22.0-35.0) U; P = 0.26].","Platelet inhibition with standard vs. lower maintenance dose of ticagrelor early after myocardial infarction (ELECTRA): a randomized, open-label, active-controlled pharmacodynamic and pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30689800/),u,26.5,7067,DB08816,Ticagrelor
>,24755129,peak inhibition,"In both groups, mean peak inhibition of platelet aggregation was > 86% after single doses (>= 100 mg ticagrelor) and > 84% after multiple doses.","Pharmacokinetics, pharmacodynamics, and tolerability of single and multiple doses of ticagrelor in Japanese and Caucasian volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24755129/),%,86,9339,DB08816,Ticagrelor
>,24755129,peak inhibition,"In both groups, mean peak inhibition of platelet aggregation was > 86% after single doses (>= 100 mg ticagrelor) and > 84% after multiple doses.","Pharmacokinetics, pharmacodynamics, and tolerability of single and multiple doses of ticagrelor in Japanese and Caucasian volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24755129/),%,84,9340,DB08816,Ticagrelor
>=,24755129,Bleeding times,Bleeding times were >= 60 minutes in more Japanese than Caucasians with multiple dosing of 100 mg and 300 mg ticagrelor Adverse events were similar between groups (mild-to-moderate intensity).,"Pharmacokinetics, pharmacodynamics, and tolerability of single and multiple doses of ticagrelor in Japanese and Caucasian volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24755129/),min,60,9341,DB08816,Ticagrelor
,27038001,maximum IPA,"With ticagrelor 45 and 90 mg twice daily, maximum IPA (mean, SD) was 91% (13%), and 99% (3%), and maximum PRU reduction from baseline (mean, SD) was 82% (17%) and 92% (9%), respectively.","Pharmacodynamics, pharmacokinetics, and safety of ticagrelor in Chinese patients with stable coronary artery disease. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27038001/),%,91,11928,DB08816,Ticagrelor
,27038001,maximum IPA,"With ticagrelor 45 and 90 mg twice daily, maximum IPA (mean, SD) was 91% (13%), and 99% (3%), and maximum PRU reduction from baseline (mean, SD) was 82% (17%) and 92% (9%), respectively.","Pharmacodynamics, pharmacokinetics, and safety of ticagrelor in Chinese patients with stable coronary artery disease. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27038001/),%,99,11929,DB08816,Ticagrelor
,27038001,Cmax,Approximate dose-proportional increases (mean [%CV]; 45 vs. 90 mg twice daily) in ticagrelor Cmax (616 [37] vs. 1273 [43] ng ml(-1) ) and AUC (3882 [42] vs. 8206 [51] ng ml(-1) h) and AR-C124910XX parameters were seen.,"Pharmacodynamics, pharmacokinetics, and safety of ticagrelor in Chinese patients with stable coronary artery disease. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27038001/),[ng] / [ml],616,11930,DB08816,Ticagrelor
,27038001,Cmax,Approximate dose-proportional increases (mean [%CV]; 45 vs. 90 mg twice daily) in ticagrelor Cmax (616 [37] vs. 1273 [43] ng ml(-1) ) and AUC (3882 [42] vs. 8206 [51] ng ml(-1) h) and AR-C124910XX parameters were seen.,"Pharmacodynamics, pharmacokinetics, and safety of ticagrelor in Chinese patients with stable coronary artery disease. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27038001/),[ng] / [ml],1273,11931,DB08816,Ticagrelor
,27038001,AUC,Approximate dose-proportional increases (mean [%CV]; 45 vs. 90 mg twice daily) in ticagrelor Cmax (616 [37] vs. 1273 [43] ng ml(-1) ) and AUC (3882 [42] vs. 8206 [51] ng ml(-1) h) and AR-C124910XX parameters were seen.,"Pharmacodynamics, pharmacokinetics, and safety of ticagrelor in Chinese patients with stable coronary artery disease. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27038001/),[h·ng] / [ml],3882,11932,DB08816,Ticagrelor
,27038001,AUC,Approximate dose-proportional increases (mean [%CV]; 45 vs. 90 mg twice daily) in ticagrelor Cmax (616 [37] vs. 1273 [43] ng ml(-1) ) and AUC (3882 [42] vs. 8206 [51] ng ml(-1) h) and AR-C124910XX parameters were seen.,"Pharmacodynamics, pharmacokinetics, and safety of ticagrelor in Chinese patients with stable coronary artery disease. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27038001/),[h·ng] / [ml],8206,11933,DB08816,Ticagrelor
,30414387,half maximal inhibition,"On average, half maximal inhibition was reached at ticagrelor concentrations of 116 (RSE: 5.3%) nmol l-1 .",Pharmacokinetic-pharmacodynamic modelling of platelet response to ticagrelor in stable coronary artery disease and prior myocardial infarction patients. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30414387/),%,116,13270,DB08816,Ticagrelor
,25064036,IC50,SAR216471 blocks the binding of 2MeSADP to P2Y12 receptors in vitro (IC50=17 nM).,"SAR216471, an alternative to the use of currently available P2Y₁₂ receptor inhibitors? ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25064036/),nM,17,22006,DB08816,Ticagrelor
,25064036,IC50,"It potently antagonized ADP-induced platelet aggregation in human and rat platelet-rich plasma (IC50=108 and 62 nM, respectively).","SAR216471, an alternative to the use of currently available P2Y₁₂ receptor inhibitors? ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25064036/),nM,108,22007,DB08816,Ticagrelor
,25064036,IC50,"It potently antagonized ADP-induced platelet aggregation in human and rat platelet-rich plasma (IC50=108 and 62 nM, respectively).","SAR216471, an alternative to the use of currently available P2Y₁₂ receptor inhibitors? ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25064036/),nM,62,22008,DB08816,Ticagrelor
,25064036,ED50,Pre-clinical study of SAR216471 in a rat shunt thrombosis model demonstrated a dose-dependent antithrombotic activity after oral administration (ED50=6.7 mg/kg).,"SAR216471, an alternative to the use of currently available P2Y₁₂ receptor inhibitors? ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25064036/),[mg] / [kg],6.7,22009,DB08816,Ticagrelor
,25064036,ED50,"By comparison, ED50 values for clopidogrel, prasugrel and ticagrelor were 6.3, 0.35 and 2.6 mg/kg, respectively.","SAR216471, an alternative to the use of currently available P2Y₁₂ receptor inhibitors? ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25064036/),[mg] / [kg],6.3,22010,DB08816,Ticagrelor
,25064036,ED50,"By comparison, ED50 values for clopidogrel, prasugrel and ticagrelor were 6.3, 0.35 and 2.6 mg/kg, respectively.","SAR216471, an alternative to the use of currently available P2Y₁₂ receptor inhibitors? ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25064036/),[mg] / [kg],0.35,22011,DB08816,Ticagrelor
,25064036,ED50,"By comparison, ED50 values for clopidogrel, prasugrel and ticagrelor were 6.3, 0.35 and 2.6 mg/kg, respectively.","SAR216471, an alternative to the use of currently available P2Y₁₂ receptor inhibitors? ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25064036/),[mg] / [kg],2.6,22012,DB08816,Ticagrelor
,20642549,t(max),"Ticagrelor was absorbed with median t(max) 1.5-3 h, exhibiting predictable pharmacokinetics over the 50-600 mg dose range.","Pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20642549/),h,1.5-3,25985,DB08816,Ticagrelor
,25069798,Cmax,"Venlafaxine Cmax was increased by 22% in the presence of ticagrelor (121.83 ng/mL [90% CI, 111.80-132.75]).","Evaluation of the pharmacokinetic interaction between ticagrelor and venlafaxine, a cytochrome P-450 2D6 substrate, in healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25069798/),[ng] / [ml],121.83,30557,DB08816,Ticagrelor
,25069798,AUC0-τ,"ODV AUC0-τ and Cmax were unaffected by coadministration with ticagrelor (98.71 ng · h/mL [90% CI, 96.61-100.85] and 101.44 ng/mL [90% CI, 98.34-104.65], respectively).","Evaluation of the pharmacokinetic interaction between ticagrelor and venlafaxine, a cytochrome P-450 2D6 substrate, in healthy subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25069798/),[h·ng] / [ml],98.71,30558,DB08816,Ticagrelor
,25069798,Cmax,"ODV AUC0-τ and Cmax were unaffected by coadministration with ticagrelor (98.71 ng · h/mL [90% CI, 96.61-100.85] and 101.44 ng/mL [90% CI, 98.34-104.65], respectively).","Evaluation of the pharmacokinetic interaction between ticagrelor and venlafaxine, a cytochrome P-450 2D6 substrate, in healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25069798/),[ng] / [ml],101.44,30559,DB08816,Ticagrelor
,25069798,Cmax,"Venlafaxine had no effect on the Cmax or AUC0-∞ of ticagrelor (96.54 ng/mL [90% CI, 85.03-109.61] and 89.67 ng · h/mL [90% CI, 82.78-97.14]) or AR-C124910XX (106.39 ng/mL [90% CI, 96.10-117.78] and 106.32 ng · h/mL [90% CI, 97.28-116.21], respectively).","Evaluation of the pharmacokinetic interaction between ticagrelor and venlafaxine, a cytochrome P-450 2D6 substrate, in healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25069798/),[ng] / [ml],96.54,30560,DB08816,Ticagrelor
,25069798,Cmax,"Venlafaxine had no effect on the Cmax or AUC0-∞ of ticagrelor (96.54 ng/mL [90% CI, 85.03-109.61] and 89.67 ng · h/mL [90% CI, 82.78-97.14]) or AR-C124910XX (106.39 ng/mL [90% CI, 96.10-117.78] and 106.32 ng · h/mL [90% CI, 97.28-116.21], respectively).","Evaluation of the pharmacokinetic interaction between ticagrelor and venlafaxine, a cytochrome P-450 2D6 substrate, in healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25069798/),[ng] / [ml],106.39,30561,DB08816,Ticagrelor
,25069798,AUC0-∞,"Venlafaxine had no effect on the Cmax or AUC0-∞ of ticagrelor (96.54 ng/mL [90% CI, 85.03-109.61] and 89.67 ng · h/mL [90% CI, 82.78-97.14]) or AR-C124910XX (106.39 ng/mL [90% CI, 96.10-117.78] and 106.32 ng · h/mL [90% CI, 97.28-116.21], respectively).","Evaluation of the pharmacokinetic interaction between ticagrelor and venlafaxine, a cytochrome P-450 2D6 substrate, in healthy subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25069798/),[h·ng] / [ml],89.67,30562,DB08816,Ticagrelor
,25069798,AUC0-∞,"Venlafaxine had no effect on the Cmax or AUC0-∞ of ticagrelor (96.54 ng/mL [90% CI, 85.03-109.61] and 89.67 ng · h/mL [90% CI, 82.78-97.14]) or AR-C124910XX (106.39 ng/mL [90% CI, 96.10-117.78] and 106.32 ng · h/mL [90% CI, 97.28-116.21], respectively).","Evaluation of the pharmacokinetic interaction between ticagrelor and venlafaxine, a cytochrome P-450 2D6 substrate, in healthy subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25069798/),[h·ng] / [ml],106.32,30563,DB08816,Ticagrelor
,29850937,maximum plasma concentration (Cmax),"The mean maximum plasma concentration (Cmax) and area under the plasma concentration curve from time zero to infinity (AUC0-∞) of ticagrelor were 598.4 ng/mL and 3256.1 ng·h/mL, respectively, in pre-hemodialysis subjects; 560.3 ng/mL and 3015.1 ng·h/mL, respectively, in post-hemodialysis subjects; and 370.8 ng/mL and 2188.8 ng·h/mL, respectively, in healthy subjects.",Pharmacokinetics and pharmacodynamics of ticagrelor in subjects on hemodialysis and subjects with normal renal function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29850937/),[ng] / [ml],598.4,32936,DB08816,Ticagrelor
,29850937,maximum plasma concentration (Cmax),"The mean maximum plasma concentration (Cmax) and area under the plasma concentration curve from time zero to infinity (AUC0-∞) of ticagrelor were 598.4 ng/mL and 3256.1 ng·h/mL, respectively, in pre-hemodialysis subjects; 560.3 ng/mL and 3015.1 ng·h/mL, respectively, in post-hemodialysis subjects; and 370.8 ng/mL and 2188.8 ng·h/mL, respectively, in healthy subjects.",Pharmacokinetics and pharmacodynamics of ticagrelor in subjects on hemodialysis and subjects with normal renal function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29850937/),[ng] / [ml],560.3,32937,DB08816,Ticagrelor
,29850937,maximum plasma concentration (Cmax),"The mean maximum plasma concentration (Cmax) and area under the plasma concentration curve from time zero to infinity (AUC0-∞) of ticagrelor were 598.4 ng/mL and 3256.1 ng·h/mL, respectively, in pre-hemodialysis subjects; 560.3 ng/mL and 3015.1 ng·h/mL, respectively, in post-hemodialysis subjects; and 370.8 ng/mL and 2188.8 ng·h/mL, respectively, in healthy subjects.",Pharmacokinetics and pharmacodynamics of ticagrelor in subjects on hemodialysis and subjects with normal renal function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29850937/),[ng] / [ml],370.8,32938,DB08816,Ticagrelor
,29850937,area under the plasma concentration curve from time zero to infinity (AUC0-∞),"The mean maximum plasma concentration (Cmax) and area under the plasma concentration curve from time zero to infinity (AUC0-∞) of ticagrelor were 598.4 ng/mL and 3256.1 ng·h/mL, respectively, in pre-hemodialysis subjects; 560.3 ng/mL and 3015.1 ng·h/mL, respectively, in post-hemodialysis subjects; and 370.8 ng/mL and 2188.8 ng·h/mL, respectively, in healthy subjects.",Pharmacokinetics and pharmacodynamics of ticagrelor in subjects on hemodialysis and subjects with normal renal function. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29850937/),[h·ng] / [ml],3256.1,32939,DB08816,Ticagrelor
,29850937,area under the plasma concentration curve from time zero to infinity (AUC0-∞),"The mean maximum plasma concentration (Cmax) and area under the plasma concentration curve from time zero to infinity (AUC0-∞) of ticagrelor were 598.4 ng/mL and 3256.1 ng·h/mL, respectively, in pre-hemodialysis subjects; 560.3 ng/mL and 3015.1 ng·h/mL, respectively, in post-hemodialysis subjects; and 370.8 ng/mL and 2188.8 ng·h/mL, respectively, in healthy subjects.",Pharmacokinetics and pharmacodynamics of ticagrelor in subjects on hemodialysis and subjects with normal renal function. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29850937/),[h·ng] / [ml],3015.1,32940,DB08816,Ticagrelor
,29850937,area under the plasma concentration curve from time zero to infinity (AUC0-∞),"The mean maximum plasma concentration (Cmax) and area under the plasma concentration curve from time zero to infinity (AUC0-∞) of ticagrelor were 598.4 ng/mL and 3256.1 ng·h/mL, respectively, in pre-hemodialysis subjects; 560.3 ng/mL and 3015.1 ng·h/mL, respectively, in post-hemodialysis subjects; and 370.8 ng/mL and 2188.8 ng·h/mL, respectively, in healthy subjects.",Pharmacokinetics and pharmacodynamics of ticagrelor in subjects on hemodialysis and subjects with normal renal function. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29850937/),[ng] / [ml],370.8,32941,DB08816,Ticagrelor
,29850937,area under the plasma concentration curve from time zero to infinity (AUC0-∞),"The mean maximum plasma concentration (Cmax) and area under the plasma concentration curve from time zero to infinity (AUC0-∞) of ticagrelor were 598.4 ng/mL and 3256.1 ng·h/mL, respectively, in pre-hemodialysis subjects; 560.3 ng/mL and 3015.1 ng·h/mL, respectively, in post-hemodialysis subjects; and 370.8 ng/mL and 2188.8 ng·h/mL, respectively, in healthy subjects.",Pharmacokinetics and pharmacodynamics of ticagrelor in subjects on hemodialysis and subjects with normal renal function. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29850937/),[h·ng] / [ml],2188.8,32942,DB08816,Ticagrelor
,29850937,Cmax,"Cmax and AUC0-∞ of AR-C124910XX, the active metabolite, were 152.3 ng/mL and 1144.2 ng·h/mL, respectively, in pre-hemodialysis subjects; 130.8 ng/mL and 1127.8 ng·h/mL, respectively, in post-hemodialysis subjects; and 111.7 ng/mL and 1000.4 ng·h/mL, respectively, in healthy subjects.",Pharmacokinetics and pharmacodynamics of ticagrelor in subjects on hemodialysis and subjects with normal renal function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29850937/),[ng] / [ml],152.3,32943,DB08816,Ticagrelor
,29850937,Cmax,"Cmax and AUC0-∞ of AR-C124910XX, the active metabolite, were 152.3 ng/mL and 1144.2 ng·h/mL, respectively, in pre-hemodialysis subjects; 130.8 ng/mL and 1127.8 ng·h/mL, respectively, in post-hemodialysis subjects; and 111.7 ng/mL and 1000.4 ng·h/mL, respectively, in healthy subjects.",Pharmacokinetics and pharmacodynamics of ticagrelor in subjects on hemodialysis and subjects with normal renal function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29850937/),[ng] / [ml],130.8,32944,DB08816,Ticagrelor
,29850937,Cmax,"Cmax and AUC0-∞ of AR-C124910XX, the active metabolite, were 152.3 ng/mL and 1144.2 ng·h/mL, respectively, in pre-hemodialysis subjects; 130.8 ng/mL and 1127.8 ng·h/mL, respectively, in post-hemodialysis subjects; and 111.7 ng/mL and 1000.4 ng·h/mL, respectively, in healthy subjects.",Pharmacokinetics and pharmacodynamics of ticagrelor in subjects on hemodialysis and subjects with normal renal function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29850937/),[ng] / [ml],111.7,32945,DB08816,Ticagrelor
,29850937,AUC0-∞,"Cmax and AUC0-∞ of AR-C124910XX, the active metabolite, were 152.3 ng/mL and 1144.2 ng·h/mL, respectively, in pre-hemodialysis subjects; 130.8 ng/mL and 1127.8 ng·h/mL, respectively, in post-hemodialysis subjects; and 111.7 ng/mL and 1000.4 ng·h/mL, respectively, in healthy subjects.",Pharmacokinetics and pharmacodynamics of ticagrelor in subjects on hemodialysis and subjects with normal renal function. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29850937/),[h·ng] / [ml],1144.2,32946,DB08816,Ticagrelor
,29850937,AUC0-∞,"Cmax and AUC0-∞ of AR-C124910XX, the active metabolite, were 152.3 ng/mL and 1144.2 ng·h/mL, respectively, in pre-hemodialysis subjects; 130.8 ng/mL and 1127.8 ng·h/mL, respectively, in post-hemodialysis subjects; and 111.7 ng/mL and 1000.4 ng·h/mL, respectively, in healthy subjects.",Pharmacokinetics and pharmacodynamics of ticagrelor in subjects on hemodialysis and subjects with normal renal function. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29850937/),[ng] / [ml],111.7,32947,DB08816,Ticagrelor
,29850937,AUC0-∞,"Cmax and AUC0-∞ of AR-C124910XX, the active metabolite, were 152.3 ng/mL and 1144.2 ng·h/mL, respectively, in pre-hemodialysis subjects; 130.8 ng/mL and 1127.8 ng·h/mL, respectively, in post-hemodialysis subjects; and 111.7 ng/mL and 1000.4 ng·h/mL, respectively, in healthy subjects.",Pharmacokinetics and pharmacodynamics of ticagrelor in subjects on hemodialysis and subjects with normal renal function. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29850937/),[h·ng] / [ml],1000.4,32948,DB08816,Ticagrelor
,28150519,Tmax,"None of the pharmacokinetic variables differed significantly between the groups, including the Tmax of ticagrelor (2.0h [1.0-3.0] versus 2.0h [2.0-3.0], p = 0.393) and the active metabolite AR-C124910XX (3.0 [2.0-4.0] versus 3.0 [2.5-4.0], p = 0.289).",Ticagrelor pharmacokinetics and pharmacodynamics in patients with NSTEMI after a 180-mg loading dose. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28150519/),h,2.0,37960,DB08816,Ticagrelor
,28150519,Tmax,"None of the pharmacokinetic variables differed significantly between the groups, including the Tmax of ticagrelor (2.0h [1.0-3.0] versus 2.0h [2.0-3.0], p = 0.393) and the active metabolite AR-C124910XX (3.0 [2.0-4.0] versus 3.0 [2.5-4.0], p = 0.289).",Ticagrelor pharmacokinetics and pharmacodynamics in patients with NSTEMI after a 180-mg loading dose. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28150519/),h,2.0,37961,DB08816,Ticagrelor
,28150519,Tmax,"None of the pharmacokinetic variables differed significantly between the groups, including the Tmax of ticagrelor (2.0h [1.0-3.0] versus 2.0h [2.0-3.0], p = 0.393) and the active metabolite AR-C124910XX (3.0 [2.0-4.0] versus 3.0 [2.5-4.0], p = 0.289).",Ticagrelor pharmacokinetics and pharmacodynamics in patients with NSTEMI after a 180-mg loading dose. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28150519/),,3.0,37962,DB08816,Ticagrelor
,28150519,Tmax,"None of the pharmacokinetic variables differed significantly between the groups, including the Tmax of ticagrelor (2.0h [1.0-3.0] versus 2.0h [2.0-3.0], p = 0.393) and the active metabolite AR-C124910XX (3.0 [2.0-4.0] versus 3.0 [2.5-4.0], p = 0.289).",Ticagrelor pharmacokinetics and pharmacodynamics in patients with NSTEMI after a 180-mg loading dose. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28150519/),,3.0,37963,DB08816,Ticagrelor
,28216475,concentrations,Ticagrelor and its main metabolite AR-C124910XX concentrations were 85.2 (37.2-178.5) and 18.3 (6.4-52.4) ng/mL.,The effect of TIcagrelor administered through a nasogastric tube to COMAtose patients undergoing acute percutaneous coronary intervention: the TICOMA study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28216475/),[ng] / [ml],85.2,42056,DB08816,Ticagrelor
,28216475,concentrations,Ticagrelor and its main metabolite AR-C124910XX concentrations were 85.2 (37.2-178.5) and 18.3 (6.4-52.4) ng/mL.,The effect of TIcagrelor administered through a nasogastric tube to COMAtose patients undergoing acute percutaneous coronary intervention: the TICOMA study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28216475/),[ng] / [ml],18.3,42057,DB08816,Ticagrelor
,28216475,times to sufficient platelet inhibition,Median times to sufficient platelet inhibition below the HPR limit were 3 (2-6) hours (VFN) and 4 (2-8) hours (Multiplate).,The effect of TIcagrelor administered through a nasogastric tube to COMAtose patients undergoing acute percutaneous coronary intervention: the TICOMA study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28216475/),h,3,42058,DB08816,Ticagrelor
,28216475,times to sufficient platelet inhibition,Median times to sufficient platelet inhibition below the HPR limit were 3 (2-6) hours (VFN) and 4 (2-8) hours (Multiplate).,The effect of TIcagrelor administered through a nasogastric tube to COMAtose patients undergoing acute percutaneous coronary intervention: the TICOMA study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28216475/),h,4,42059,DB08816,Ticagrelor
,31500011,relative bioavailability,"In vivo pharmacokinetic study, the relative bioavailability of Sol-TCG-SM exhibited 108.1% and 632.7% compared to TCG-SM and raw TCG powder, respectively.",Statistical approach for solidifying ticagrelor loaded self-microemulsifying drug delivery system with enhanced dissolution and oral bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31500011/),%,108.1,44112,DB08816,Ticagrelor
,31500011,relative bioavailability,"In vivo pharmacokinetic study, the relative bioavailability of Sol-TCG-SM exhibited 108.1% and 632.7% compared to TCG-SM and raw TCG powder, respectively.",Statistical approach for solidifying ticagrelor loaded self-microemulsifying drug delivery system with enhanced dissolution and oral bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31500011/),%,632.7,44113,DB08816,Ticagrelor
,21967645,time to maximum concentration (t(max),Ticagrelor median time to maximum concentration (t(max); 2·5 h vs. 1·5 h) was slightly delayed in the fed vs. fasting state.,Lack of significant food effect on the pharmacokinetics of ticagrelor in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21967645/),h,2·5,55330,DB08816,Ticagrelor
,21967645,time to maximum concentration (t(max),Ticagrelor median time to maximum concentration (t(max); 2·5 h vs. 1·5 h) was slightly delayed in the fed vs. fasting state.,Lack of significant food effect on the pharmacokinetics of ticagrelor in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21967645/),h,1·5,55331,DB08816,Ticagrelor
,21967645,t(max),Median t(max) of the metabolite was slightly longer in the fed than fasting state (3·5 h vs. 1·5 h).,Lack of significant food effect on the pharmacokinetics of ticagrelor in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21967645/),h,3·5,55332,DB08816,Ticagrelor
,21967645,t(max),Median t(max) of the metabolite was slightly longer in the fed than fasting state (3·5 h vs. 1·5 h).,Lack of significant food effect on the pharmacokinetics of ticagrelor in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21967645/),h,1·5,55333,DB08816,Ticagrelor
,30799546,AUC(0-12),"In patients treated with MTH total exposure to ticagrelor during the first 12 h after the loading dose and maximal plasma concentration of ticagrelor were significantly lower than in the no-MTH group (AUC(0-12): 3403 ± 2879 vs. 8746 ± 5596 ng·h/mL, difference: 61%, p = 0.01; Cmax: 475 ± 353 vs. 1568 ± 784 ng/mL, p = 0.0002).",Impact of mild therapeutic hypothermia on bioavailability of ticagrelor in patients with acute myocardial infarction after out-of-hospital cardiac arrest. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30799546/),[h·ng] / [ml],3403,58868,DB08816,Ticagrelor
,30799546,AUC(0-12),"In patients treated with MTH total exposure to ticagrelor during the first 12 h after the loading dose and maximal plasma concentration of ticagrelor were significantly lower than in the no-MTH group (AUC(0-12): 3403 ± 2879 vs. 8746 ± 5596 ng·h/mL, difference: 61%, p = 0.01; Cmax: 475 ± 353 vs. 1568 ± 784 ng/mL, p = 0.0002).",Impact of mild therapeutic hypothermia on bioavailability of ticagrelor in patients with acute myocardial infarction after out-of-hospital cardiac arrest. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30799546/),[h·ng] / [ml],8746,58869,DB08816,Ticagrelor
,30799546,Cmax,"In patients treated with MTH total exposure to ticagrelor during the first 12 h after the loading dose and maximal plasma concentration of ticagrelor were significantly lower than in the no-MTH group (AUC(0-12): 3403 ± 2879 vs. 8746 ± 5596 ng·h/mL, difference: 61%, p = 0.01; Cmax: 475 ± 353 vs. 1568 ± 784 ng/mL, p = 0.0002).",Impact of mild therapeutic hypothermia on bioavailability of ticagrelor in patients with acute myocardial infarction after out-of-hospital cardiac arrest. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30799546/),[ng] / [ml],475,58870,DB08816,Ticagrelor
,30799546,Cmax,"In patients treated with MTH total exposure to ticagrelor during the first 12 h after the loading dose and maximal plasma concentration of ticagrelor were significantly lower than in the no-MTH group (AUC(0-12): 3403 ± 2879 vs. 8746 ± 5596 ng·h/mL, difference: 61%, p = 0.01; Cmax: 475 ± 353 vs. 1568 ± 784 ng/mL, p = 0.0002).",Impact of mild therapeutic hypothermia on bioavailability of ticagrelor in patients with acute myocardial infarction after out-of-hospital cardiac arrest. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30799546/),[ng] / [ml],1568,58871,DB08816,Ticagrelor
,30799546,tmax,"Time to achieve maximal ticagrelor plasma concentration was also delayed in the MTH group (tmax for ticagrelor: 12 [6-24] vs. 4 [2-12] h, p = 0.01).",Impact of mild therapeutic hypothermia on bioavailability of ticagrelor in patients with acute myocardial infarction after out-of-hospital cardiac arrest. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30799546/),h,12,58872,DB08816,Ticagrelor
,30799546,tmax,"Time to achieve maximal ticagrelor plasma concentration was also delayed in the MTH group (tmax for ticagrelor: 12 [6-24] vs. 4 [2-12] h, p = 0.01).",Impact of mild therapeutic hypothermia on bioavailability of ticagrelor in patients with acute myocardial infarction after out-of-hospital cardiac arrest. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30799546/),h,4,58873,DB08816,Ticagrelor
,30936830,time to recover 50% of the maximum drug effect (RT50),"The time to recover 50% of the maximum drug effect (RT50) ranging from 36 to 126 h with 46.9% CV had a remarkable individual difference and was positively associated with the half-life (t1/2) of M8 (r = 0.3901, P = 0.0067).",Pharmacokinetic and Pharmacogenetic Factors Contributing to Platelet Function Recovery After Single Dose of Ticagrelor in Healthy Subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30936830/),h,36 to 126,61457,DB08816,Ticagrelor
,32157685,IC50,"TPE effectively inhibited the metabolism of ticagrelor in vitro, with epigallocatechin-3-gallate as the major constituent responsible for the observed inhibitory effects in human liver microsomes and intestinal microsomes (IC50 = 4.23 ± 0.18 µM).",Effect of tea polyphenols on the oral and intravenous pharmacokinetics of ticagrelor in rats and its in vitro metabolism. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32157685/),μM,4.23,63907,DB08816,Ticagrelor
,27536453,absolute bioavailability,The mean absolute bioavailability of ticagrelor was 36% (95% confidence interval = 30-42%).,Absolute bioavailability and regional absorption of ticagrelor in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27536453/),%,36,69345,DB08816,Ticagrelor
,27536453,absolute bioavailability,"The mean absolute bioavailability of ticagrelor was 36% and the proportion of ticagrelor absorbed decreased the further down the GI tract it was released: the mean AUC for ticagrelor was 89% (proximal small bowel), 73% (distal small bowel), and 32% (ascending colon) that of the mean AUC for the orally administered suspension.",Absolute bioavailability and regional absorption of ticagrelor in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27536453/),%,36,69346,DB08816,Ticagrelor
,27536453,AUC,"The mean absolute bioavailability of ticagrelor was 36% and the proportion of ticagrelor absorbed decreased the further down the GI tract it was released: the mean AUC for ticagrelor was 89% (proximal small bowel), 73% (distal small bowel), and 32% (ascending colon) that of the mean AUC for the orally administered suspension.",Absolute bioavailability and regional absorption of ticagrelor in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27536453/),%,89,69347,DB08816,Ticagrelor
,27536453,AUC,"The mean absolute bioavailability of ticagrelor was 36% and the proportion of ticagrelor absorbed decreased the further down the GI tract it was released: the mean AUC for ticagrelor was 89% (proximal small bowel), 73% (distal small bowel), and 32% (ascending colon) that of the mean AUC for the orally administered suspension.",Absolute bioavailability and regional absorption of ticagrelor in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27536453/),%,73,69348,DB08816,Ticagrelor
,27536453,AUC,"The mean absolute bioavailability of ticagrelor was 36% and the proportion of ticagrelor absorbed decreased the further down the GI tract it was released: the mean AUC for ticagrelor was 89% (proximal small bowel), 73% (distal small bowel), and 32% (ascending colon) that of the mean AUC for the orally administered suspension.",Absolute bioavailability and regional absorption of ticagrelor in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27536453/),%,32,69349,DB08816,Ticagrelor
,22489610,time to maximum concentration,"Ticagrelor is rapidly absorbed, with a median time to maximum concentration of 1.3-2.0 hours.","Pharmacokinetic, pharmacodynamic and pharmacogenetic profile of the oral antiplatelet agent ticagrelor. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22489610/),h,1.3-2.0,79556,DB08816,Ticagrelor
,31071977,oral bioavailability,"In pharmacokinetic study, the oral bioavailability of TGL-NLC was 254.99% higher than that of raw TGL.",Systemic Design and Evaluation of Ticagrelor-Loaded Nanostructured Lipid Carriers for Enhancing Bioavailability and Antiplatelet Activity. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31071977/),%,254.99,91553,DB08816,Ticagrelor
,22367426,time to maximum concentration (C(max)) (t(max)),"Ticagrelor was rapidly absorbed [time to maximum concentration (C(max)) (t(max)) 2.5-3.0 h], and its major active metabolite, AR-C124910XX rapidly formed (t(max) 3.0-3.5 h) in all groups.",Effect of age and gender on pharmacokinetics and pharmacodynamics of a single ticagrelor dose in healthy individuals. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22367426/),h,2.5-3.0,92975,DB08816,Ticagrelor
,22367426,t(max),"Ticagrelor was rapidly absorbed [time to maximum concentration (C(max)) (t(max)) 2.5-3.0 h], and its major active metabolite, AR-C124910XX rapidly formed (t(max) 3.0-3.5 h) in all groups.",Effect of age and gender on pharmacokinetics and pharmacodynamics of a single ticagrelor dose in healthy individuals. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22367426/),h,3.0-3.5,92976,DB08816,Ticagrelor
,30636504,time,Median (interquartile range) time from ticagrelor administration to randomization was 41 (31-50) versus 45.5 (37-60) minutes ( P=0.16).,The MOVEMENT Trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30636504/),min,41,94855,DB08816,Ticagrelor
,30636504,time,Median (interquartile range) time from ticagrelor administration to randomization was 41 (31-50) versus 45.5 (37-60) minutes ( P=0.16).,The MOVEMENT Trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30636504/),min,45.5,94856,DB08816,Ticagrelor
,25697420,Tmax,"Both ticagrelor and prasugrel were rapidly absorbed, with the shortest median Tmax of 2.0 and 2.25 hours for ticagrelor and AR-C124910XX, respectively, and a Tmax of 0.5 hour for both R-95913 and R-138727.",Pharmacokinetics and pharmacodynamics of ticagrelor and prasugrel in healthy male Korean volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25697420/),h,2.0,96562,DB08816,Ticagrelor
,25697420,Tmax,"Both ticagrelor and prasugrel were rapidly absorbed, with the shortest median Tmax of 2.0 and 2.25 hours for ticagrelor and AR-C124910XX, respectively, and a Tmax of 0.5 hour for both R-95913 and R-138727.",Pharmacokinetics and pharmacodynamics of ticagrelor and prasugrel in healthy male Korean volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25697420/),h,2.25,96563,DB08816,Ticagrelor
,25697420,Tmax,"Both ticagrelor and prasugrel were rapidly absorbed, with the shortest median Tmax of 2.0 and 2.25 hours for ticagrelor and AR-C124910XX, respectively, and a Tmax of 0.5 hour for both R-95913 and R-138727.",Pharmacokinetics and pharmacodynamics of ticagrelor and prasugrel in healthy male Korean volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25697420/),h,0.5,96564,DB08816,Ticagrelor
,23126367,elimination half-life,Grapefruit juice had a minor effect on ticagrelor elimination half-life prolonging it from 6.7 to 7.2 h (P = 0.036).,Grapefruit juice markedly increases the plasma concentrations and antiplatelet effects of ticagrelor in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23126367/),h,6.7 to 7.2,96591,DB08816,Ticagrelor
,30448313,peak plasma concentration (Cmax),"The solid dispersion formulation improved the peak plasma concentration (Cmax) and relative bioavailability compared to that of pure drug as 238.09 ± 25.96% and 219.78 ± 36.33%, respectively, after oral administration in rats.",A novel composition of ticagrelor by solid dispersion technique for increasing solubility and intestinal permeability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30448313/),%,238.09,101782,DB08816,Ticagrelor
,30448313,relative bioavailability,"The solid dispersion formulation improved the peak plasma concentration (Cmax) and relative bioavailability compared to that of pure drug as 238.09 ± 25.96% and 219.78 ± 36.33%, respectively, after oral administration in rats.",A novel composition of ticagrelor by solid dispersion technique for increasing solubility and intestinal permeability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30448313/),%,219.78,101783,DB08816,Ticagrelor
,20688583,Total analytical run time,Total analytical run time was short (2 min).,Determination of ticagrelor and two metabolites in plasma samples by liquid chromatography and mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20688583/),min,2,104647,DB08816,Ticagrelor
,33400617,half-maximal inhibitory concentration,"The half-maximal inhibitory concentration values of resveratrol were 56.75 μM, 69.07 μM, and 14.22 μM, respectively.",Inhibitory effect of resveratrol on the pharmacokinetics of ticagrelor in vivo and in vitro. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33400617/),μM,56.75,117862,DB08816,Ticagrelor
,33400617,half-maximal inhibitory concentration,"The half-maximal inhibitory concentration values of resveratrol were 56.75 μM, 69.07 μM, and 14.22 μM, respectively.",Inhibitory effect of resveratrol on the pharmacokinetics of ticagrelor in vivo and in vitro. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33400617/),μM,69.07,117863,DB08816,Ticagrelor
,33400617,half-maximal inhibitory concentration,"The half-maximal inhibitory concentration values of resveratrol were 56.75 μM, 69.07 μM, and 14.22 μM, respectively.",Inhibitory effect of resveratrol on the pharmacokinetics of ticagrelor in vivo and in vitro. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33400617/),μM,14.22,117864,DB08816,Ticagrelor
,30972696,oral clearances,Estimated oral clearances (35 kg patient; median bodyweight) were 22.8 L/h (ticagrelor) and 9.97 L/h (AR-C124910XX).,Population Pharmacokinetics/Pharmacodynamics of Ticagrelor in Children with Sickle Cell Disease. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30972696/),[l] / [h],22.8,120578,DB08816,Ticagrelor
,30972696,oral clearances,Estimated oral clearances (35 kg patient; median bodyweight) were 22.8 L/h (ticagrelor) and 9.97 L/h (AR-C124910XX).,Population Pharmacokinetics/Pharmacodynamics of Ticagrelor in Children with Sickle Cell Disease. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30972696/),[l] / [h],9.97,120579,DB08816,Ticagrelor
,30972696,maximum PRU effect,"Estimated baseline PRU was 283, maximum PRU effect was fixed at 1, and the ticagrelor concentration for half-maximum PRU effect was 233 nmol/L.",Population Pharmacokinetics/Pharmacodynamics of Ticagrelor in Children with Sickle Cell Disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30972696/),,1,120580,DB08816,Ticagrelor
,30972696,half-maximum PRU effect,"Estimated baseline PRU was 283, maximum PRU effect was fixed at 1, and the ticagrelor concentration for half-maximum PRU effect was 233 nmol/L.",Population Pharmacokinetics/Pharmacodynamics of Ticagrelor in Children with Sickle Cell Disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30972696/),[nM] / [l],233,120581,DB08816,Ticagrelor
,20091161,time to peak plasma concentration (t(max)),"Absorption of ticagrelor was rapid [median time to peak plasma concentration (t(max)) 1.3-2 h], as was the formation of its main (active) metabolite, AR-C124910XX (t(max) 1.5-3 h).","Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y(12) receptor antagonist, in healthy subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20091161/),h,1.3-2,124637,DB08816,Ticagrelor
,20091161,t(max),"Absorption of ticagrelor was rapid [median time to peak plasma concentration (t(max)) 1.3-2 h], as was the formation of its main (active) metabolite, AR-C124910XX (t(max) 1.5-3 h).","Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y(12) receptor antagonist, in healthy subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20091161/),h,1.5-3,124638,DB08816,Ticagrelor
,20091161,terminal-phase half-life (t(1/2)),The mean terminal-phase half-life (t(1/2)) was approximately 7-8.5 h for ticagrelor and 8.5-10 h for AR-C124910XX; AR-C124910XX exposure was approximately one third that of ticagrelor.,"Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y(12) receptor antagonist, in healthy subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20091161/),h,7-8.5,124639,DB08816,Ticagrelor
,20091161,terminal-phase half-life (t(1/2)),The mean terminal-phase half-life (t(1/2)) was approximately 7-8.5 h for ticagrelor and 8.5-10 h for AR-C124910XX; AR-C124910XX exposure was approximately one third that of ticagrelor.,"Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y(12) receptor antagonist, in healthy subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20091161/),h,8.5-10,124640,DB08816,Ticagrelor
,21692601,t(max),"Ethinyl oestradiol absorption was rapid (median t(max) approximately 1 hour), and was not affected by ticagrelor.",Effect of ticagrelor on the pharmacokinetics of ethinyl oestradiol and levonorgestrel in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21692601/),h,1,133521,DB08816,Ticagrelor
,28139972,apparent clearance (CL/F),Ticagrelor apparent clearance (CL/F) was 17 L/h for the 60-mg and 15.4 L/h for the 90-mg dose.,Population pharmacokinetics of ticagrelor and AR-C124910XX in patients with prior myocardial infarction . ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28139972/),[l] / [h],17,144100,DB08816,Ticagrelor
,28139972,apparent clearance (CL/F),Ticagrelor apparent clearance (CL/F) was 17 L/h for the 60-mg and 15.4 L/h for the 90-mg dose.,Population pharmacokinetics of ticagrelor and AR-C124910XX in patients with prior myocardial infarction . ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28139972/),[l] / [h],15.4,144101,DB08816,Ticagrelor
,28139972,CL/F,The CL/F of AR-C124910XX was 11.1 L/h for the 60-mg and 9.95 L/h for the 90-mg dose.,Population pharmacokinetics of ticagrelor and AR-C124910XX in patients with prior myocardial infarction . ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28139972/),[l] / [h],11.1,144102,DB08816,Ticagrelor
,28139972,CL/F,The CL/F of AR-C124910XX was 11.1 L/h for the 60-mg and 9.95 L/h for the 90-mg dose.,Population pharmacokinetics of ticagrelor and AR-C124910XX in patients with prior myocardial infarction . ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28139972/),[l] / [h],9.95,144103,DB08816,Ticagrelor
,32770531,Tmax,Tmax of metabolite AR-C124910XX was 4 h after LD for both groups.,Ticagrelor Pharmacokinetics and Pharmacodynamics in Chinese Patients with STEMI and NSTEMI Without Opioid Administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32770531/),h,4,145309,DB08816,Ticagrelor
,32763840,lowest detectable concentrations,"Lowest concentrations that could be quantitated using the native and first derivative synchronous methods were 189 and 151 ng/mL while lowest detectable concentrations were 63 and 50 ng/mL, respectively.",Rapid fluorometric determination of ticagrelor in tablets and rat plasma: Application to pharmacokinetics study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32763840/),[ng] / [ml],63,146478,DB08816,Ticagrelor
,32763840,lowest detectable concentrations,"Lowest concentrations that could be quantitated using the native and first derivative synchronous methods were 189 and 151 ng/mL while lowest detectable concentrations were 63 and 50 ng/mL, respectively.",Rapid fluorometric determination of ticagrelor in tablets and rat plasma: Application to pharmacokinetics study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32763840/),[ng] / [ml],50,146479,DB08816,Ticagrelor
,26315810,area under the plasma concentration-time curve from time zero to 1 h (AUC1),"At 1 h, ticagrelor plasma exposure and area under the plasma concentration-time curve from time zero to 1 h (AUC1) (co-primary endpoints) were higher in the crushed versus integral tablets group (median 586 vs. 70.1 ng/mL and 234 vs. 24.4 ng·h/mL, respectively), with a ratio of adjusted geometric means (95% confidence interval [CI]) of 12.67 (2.34-68.51) [p = 0.005] and 19.28 (3.51-106.06) [p = 0.002], respectively.",Crushed Versus Integral Tablets of Ticagrelor in ST-Segment Elevation Myocardial Infarction Patients: A Randomized Pharmacokinetic/Pharmacodynamic Study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26315810/),[ng] / [ml],586,146646,DB08816,Ticagrelor
,26315810,area under the plasma concentration-time curve from time zero to 1 h (AUC1),"At 1 h, ticagrelor plasma exposure and area under the plasma concentration-time curve from time zero to 1 h (AUC1) (co-primary endpoints) were higher in the crushed versus integral tablets group (median 586 vs. 70.1 ng/mL and 234 vs. 24.4 ng·h/mL, respectively), with a ratio of adjusted geometric means (95% confidence interval [CI]) of 12.67 (2.34-68.51) [p = 0.005] and 19.28 (3.51-106.06) [p = 0.002], respectively.",Crushed Versus Integral Tablets of Ticagrelor in ST-Segment Elevation Myocardial Infarction Patients: A Randomized Pharmacokinetic/Pharmacodynamic Study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26315810/),[ng] / [ml],70.1,146647,DB08816,Ticagrelor
,26315810,area under the plasma concentration-time curve from time zero to 1 h (AUC1),"At 1 h, ticagrelor plasma exposure and area under the plasma concentration-time curve from time zero to 1 h (AUC1) (co-primary endpoints) were higher in the crushed versus integral tablets group (median 586 vs. 70.1 ng/mL and 234 vs. 24.4 ng·h/mL, respectively), with a ratio of adjusted geometric means (95% confidence interval [CI]) of 12.67 (2.34-68.51) [p = 0.005] and 19.28 (3.51-106.06) [p = 0.002], respectively.",Crushed Versus Integral Tablets of Ticagrelor in ST-Segment Elevation Myocardial Infarction Patients: A Randomized Pharmacokinetic/Pharmacodynamic Study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26315810/),[h·ng] / [ml],234,146648,DB08816,Ticagrelor
,26315810,area under the plasma concentration-time curve from time zero to 1 h (AUC1),"At 1 h, ticagrelor plasma exposure and area under the plasma concentration-time curve from time zero to 1 h (AUC1) (co-primary endpoints) were higher in the crushed versus integral tablets group (median 586 vs. 70.1 ng/mL and 234 vs. 24.4 ng·h/mL, respectively), with a ratio of adjusted geometric means (95% confidence interval [CI]) of 12.67 (2.34-68.51) [p = 0.005] and 19.28 (3.51-106.06) [p = 0.002], respectively.",Crushed Versus Integral Tablets of Ticagrelor in ST-Segment Elevation Myocardial Infarction Patients: A Randomized Pharmacokinetic/Pharmacodynamic Study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26315810/),[h·ng] / [ml],24.4,146649,DB08816,Ticagrelor
,26315810,Time to maximum plasma concentration,"Time to maximum plasma concentration was shorter in the crushed versus integral tablets group (median 2 vs. 4 h), with a ratio of adjusted geometric means (95% CI) of 0.69 (0.49-0.97) [p = 0.035].",Crushed Versus Integral Tablets of Ticagrelor in ST-Segment Elevation Myocardial Infarction Patients: A Randomized Pharmacokinetic/Pharmacodynamic Study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26315810/),h,2,146650,DB08816,Ticagrelor
,26315810,Time to maximum plasma concentration,"Time to maximum plasma concentration was shorter in the crushed versus integral tablets group (median 2 vs. 4 h), with a ratio of adjusted geometric means (95% CI) of 0.69 (0.49-0.97) [p = 0.035].",Crushed Versus Integral Tablets of Ticagrelor in ST-Segment Elevation Myocardial Infarction Patients: A Randomized Pharmacokinetic/Pharmacodynamic Study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26315810/),h,4,146651,DB08816,Ticagrelor
,34423354,area under the plasma-time curves,"The area under the plasma-time curves for ticagrelor (1228 vs. 2753 ng h/mL, P < 0.001) and its active metabolite (201 vs. 447 ng h/mL, P = 0.001) were both significantly lower in the fentanyl arm.",Effects of lignocaine vs. opioids on antiplatelet activity of ticagrelor: the LOCAL trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34423354/),[h·ng] / [ml],1228,148719,DB08816,Ticagrelor
,34423354,area under the plasma-time curves,"The area under the plasma-time curves for ticagrelor (1228 vs. 2753 ng h/mL, P < 0.001) and its active metabolite (201 vs. 447 ng h/mL, P = 0.001) were both significantly lower in the fentanyl arm.",Effects of lignocaine vs. opioids on antiplatelet activity of ticagrelor: the LOCAL trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34423354/),[h·ng] / [ml],2753,148720,DB08816,Ticagrelor
,34423354,area under the plasma-time curves,"The area under the plasma-time curves for ticagrelor (1228 vs. 2753 ng h/mL, P < 0.001) and its active metabolite (201 vs. 447 ng h/mL, P = 0.001) were both significantly lower in the fentanyl arm.",Effects of lignocaine vs. opioids on antiplatelet activity of ticagrelor: the LOCAL trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34423354/),[h·ng] / [ml],201,148721,DB08816,Ticagrelor
,34423354,area under the plasma-time curves,"The area under the plasma-time curves for ticagrelor (1228 vs. 2753 ng h/mL, P < 0.001) and its active metabolite (201 vs. 447 ng h/mL, P = 0.001) were both significantly lower in the fentanyl arm.",Effects of lignocaine vs. opioids on antiplatelet activity of ticagrelor: the LOCAL trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34423354/),[h·ng] / [ml],447,148722,DB08816,Ticagrelor
,27191766,firstorder absorption rate constant,"A one-compartment model with population mean PK parameters of firstorder absorption rate constant (0.67/h), apparent systemic clearance (14 L/h), and apparent volume of distribution (221 L) was shown to best describe the PK profile of ticagrelor.",Population pharmacokinetics of ticagrelor in patients with acute coronary syndromes. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27191766/),1/[h],0.67,154909,DB08816,Ticagrelor
,27191766,apparent systemic clearance,"A one-compartment model with population mean PK parameters of firstorder absorption rate constant (0.67/h), apparent systemic clearance (14 L/h), and apparent volume of distribution (221 L) was shown to best describe the PK profile of ticagrelor.",Population pharmacokinetics of ticagrelor in patients with acute coronary syndromes. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27191766/),[l] / [h],14,154910,DB08816,Ticagrelor
,27191766,apparent volume of distribution,"A one-compartment model with population mean PK parameters of firstorder absorption rate constant (0.67/h), apparent systemic clearance (14 L/h), and apparent volume of distribution (221 L) was shown to best describe the PK profile of ticagrelor.",Population pharmacokinetics of ticagrelor in patients with acute coronary syndromes. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27191766/),l,221,154911,DB08816,Ticagrelor
,27191766,bioavailability,"Ticagrelor bioavailability was 21% (95% CI, 19 - 22%) lower at treatment initiation (visit 1) versus subsequent visits.",Population pharmacokinetics of ticagrelor in patients with acute coronary syndromes. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27191766/),%,21,154912,DB08816,Ticagrelor
,27191766,bioavailability,"Compared with Caucasian patients, ticagrelor bioavailability was 39% (95% CI, 33 - 46%) higher in Asian patients and 18% (95% CI, 6 - 28%) lower in Black patients.",Population pharmacokinetics of ticagrelor in patients with acute coronary syndromes. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27191766/),%,39,154913,DB08816,Ticagrelor
,27191766,bioavailability,"Compared with Caucasian patients, ticagrelor bioavailability was 39% (95% CI, 33 - 46%) higher in Asian patients and 18% (95% CI, 6 - 28%) lower in Black patients.",Population pharmacokinetics of ticagrelor in patients with acute coronary syndromes. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27191766/),%,18,154914,DB08816,Ticagrelor
,24861133,AUC(,Co-administration of cyclosporine with ticagrelor significantly increased AR-C124910XX AUC(∞) (1.33 [1.23-1.42]) and decreased C(max) (0.85 [0.76-0.94]).,Pharmacokinetic interaction study of ticagrelor and cyclosporine in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24861133/),,1,157947,DB08816,Ticagrelor
,28921624,time to reach maximum concentration (Cmax ),"Ticagrelor and its active metabolite AR-C124910XX showed a similar time to reach maximum concentration (Cmax ) of 8 h, with the maximum concentration (Cmax ) of 355 (242.50-522.00) ng ml-1 and 63.20 (50.80-85.15) ng ml-1 , respectively.",Pharmacodynamics and pharmacokinetics of ticagrelor vs. clopidogrel in patients with acute coronary syndromes and chronic kidney disease. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28921624/),h,8,162329,DB08816,Ticagrelor
,28921624,maximum concentration (Cmax ),"Ticagrelor and its active metabolite AR-C124910XX showed a similar time to reach maximum concentration (Cmax ) of 8 h, with the maximum concentration (Cmax ) of 355 (242.50-522.00) ng ml-1 and 63.20 (50.80-85.15) ng ml-1 , respectively.",Pharmacodynamics and pharmacokinetics of ticagrelor vs. clopidogrel in patients with acute coronary syndromes and chronic kidney disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28921624/),[ng] / [ml],355,162330,DB08816,Ticagrelor
,28921624,maximum concentration (Cmax ),"Ticagrelor and its active metabolite AR-C124910XX showed a similar time to reach maximum concentration (Cmax ) of 8 h, with the maximum concentration (Cmax ) of 355 (242.50-522.00) ng ml-1 and 63.20 (50.80-85.15) ng ml-1 , respectively.",Pharmacodynamics and pharmacokinetics of ticagrelor vs. clopidogrel in patients with acute coronary syndromes and chronic kidney disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28921624/),[ng] / [ml],63.20,162331,DB08816,Ticagrelor
,28921624,Cmax,"Both clopidogrel and its active metabolite approached the Cmax at 2 h, with a similar Cmax of 8.67 (6.64-27.75) ng ml-1 vs. 8.53 (6.94-15.93) ng ml-1 .",Pharmacodynamics and pharmacokinetics of ticagrelor vs. clopidogrel in patients with acute coronary syndromes and chronic kidney disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28921624/),[ng] / [ml],8.67,162332,DB08816,Ticagrelor
,28921624,Cmax,"Both clopidogrel and its active metabolite approached the Cmax at 2 h, with a similar Cmax of 8.67 (6.64-27.75) ng ml-1 vs. 8.53 (6.94-15.93) ng ml-1 .",Pharmacodynamics and pharmacokinetics of ticagrelor vs. clopidogrel in patients with acute coronary syndromes and chronic kidney disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28921624/),[ng] / [ml],8.53,162333,DB08816,Ticagrelor
,28203684,area under the plasma concentration-time curve,"The area under the plasma concentration-time curve for ticagrelor and AR-C124900XX was significantly higher in patients treated with crushed tablets given orally compared with crushed tablets given sublingually only within the first hour after loading dose (936.9 ± 898.0 vs 368.0 ± 422.4, p=0.042 and 103.4 ± 120.8 vs 31.3 ± 43.9, p=0.031, respectively).",Crushed sublingual versus oral ticagrelor administration strategies in patients with unstable angina. A pharmacokinetic/pharmacodynamic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28203684/),,936.9,168270,DB08816,Ticagrelor
,28203684,area under the plasma concentration-time curve,"The area under the plasma concentration-time curve for ticagrelor and AR-C124900XX was significantly higher in patients treated with crushed tablets given orally compared with crushed tablets given sublingually only within the first hour after loading dose (936.9 ± 898.0 vs 368.0 ± 422.4, p=0.042 and 103.4 ± 120.8 vs 31.3 ± 43.9, p=0.031, respectively).",Crushed sublingual versus oral ticagrelor administration strategies in patients with unstable angina. A pharmacokinetic/pharmacodynamic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28203684/),,368.0,168271,DB08816,Ticagrelor
,28203684,area under the plasma concentration-time curve,"The area under the plasma concentration-time curve for ticagrelor and AR-C124900XX was significantly higher in patients treated with crushed tablets given orally compared with crushed tablets given sublingually only within the first hour after loading dose (936.9 ± 898.0 vs 368.0 ± 422.4, p=0.042 and 103.4 ± 120.8 vs 31.3 ± 43.9, p=0.031, respectively).",Crushed sublingual versus oral ticagrelor administration strategies in patients with unstable angina. A pharmacokinetic/pharmacodynamic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28203684/),,103.4,168272,DB08816,Ticagrelor
,28203684,area under the plasma concentration-time curve,"The area under the plasma concentration-time curve for ticagrelor and AR-C124900XX was significantly higher in patients treated with crushed tablets given orally compared with crushed tablets given sublingually only within the first hour after loading dose (936.9 ± 898.0 vs 368.0 ± 422.4, p=0.042 and 103.4 ± 120.8 vs 31.3 ± 43.9, p=0.031, respectively).",Crushed sublingual versus oral ticagrelor administration strategies in patients with unstable angina. A pharmacokinetic/pharmacodynamic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28203684/),,31.3,168273,DB08816,Ticagrelor
,32633174,C max,The C max (221.34 ± 53.33 vs. 691.18 ± 238.31 ng/mL) and the AUC(0-t) (1060.97 ± 291.21 vs. 3483.03 ± 753.83 μg·h/L) of rivaroxaban increased significantly (p < 0.05) with ticagrelor pre-treatment.,Effects of ticagrelor on the pharmacokinetics of rivaroxaban in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32633174/),[ng] / [ml],221.34,172770,DB08816,Ticagrelor
,32633174,C max,The C max (221.34 ± 53.33 vs. 691.18 ± 238.31 ng/mL) and the AUC(0-t) (1060.97 ± 291.21 vs. 3483.03 ± 753.83 μg·h/L) of rivaroxaban increased significantly (p < 0.05) with ticagrelor pre-treatment.,Effects of ticagrelor on the pharmacokinetics of rivaroxaban in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32633174/),[ng] / [ml],691.18,172771,DB08816,Ticagrelor
,32633174,AUC(0-t),The C max (221.34 ± 53.33 vs. 691.18 ± 238.31 ng/mL) and the AUC(0-t) (1060.97 ± 291.21 vs. 3483.03 ± 753.83 μg·h/L) of rivaroxaban increased significantly (p < 0.05) with ticagrelor pre-treatment.,Effects of ticagrelor on the pharmacokinetics of rivaroxaban in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32633174/),[h·μg] / [l],1060.97,172772,DB08816,Ticagrelor
,32633174,AUC(0-t),The C max (221.34 ± 53.33 vs. 691.18 ± 238.31 ng/mL) and the AUC(0-t) (1060.97 ± 291.21 vs. 3483.03 ± 753.83 μg·h/L) of rivaroxaban increased significantly (p < 0.05) with ticagrelor pre-treatment.,Effects of ticagrelor on the pharmacokinetics of rivaroxaban in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32633174/),[h·μg] / [l],3483.03,172773,DB08816,Ticagrelor
,32633174,MRT(0-∞),"The MRT(0-∞) of rivaroxaban increased from 4.41 ± 0.79 to 5.97 ± 1.11 h, while the intrinsic clearance decreased from 9.93 ± 2.55 to 2.89 ± 0.63 L/h/kg (both p < 0.05) after pre-treated with ticagrelor.",Effects of ticagrelor on the pharmacokinetics of rivaroxaban in rats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32633174/),h,4.41,172774,DB08816,Ticagrelor
,32633174,MRT(0-∞),"The MRT(0-∞) of rivaroxaban increased from 4.41 ± 0.79 to 5.97 ± 1.11 h, while the intrinsic clearance decreased from 9.93 ± 2.55 to 2.89 ± 0.63 L/h/kg (both p < 0.05) after pre-treated with ticagrelor.",Effects of ticagrelor on the pharmacokinetics of rivaroxaban in rats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32633174/),h,5.97,172775,DB08816,Ticagrelor
,32633174,intrinsic clearance,"The MRT(0-∞) of rivaroxaban increased from 4.41 ± 0.79 to 5.97 ± 1.11 h, while the intrinsic clearance decreased from 9.93 ± 2.55 to 2.89 ± 0.63 L/h/kg (both p < 0.05) after pre-treated with ticagrelor.",Effects of ticagrelor on the pharmacokinetics of rivaroxaban in rats. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32633174/),[l] / [h·kg],9.93,172776,DB08816,Ticagrelor
,32633174,intrinsic clearance,"The MRT(0-∞) of rivaroxaban increased from 4.41 ± 0.79 to 5.97 ± 1.11 h, while the intrinsic clearance decreased from 9.93 ± 2.55 to 2.89 ± 0.63 L/h/kg (both p < 0.05) after pre-treated with ticagrelor.",Effects of ticagrelor on the pharmacokinetics of rivaroxaban in rats. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32633174/),[l] / [h·kg],2.89,172777,DB08816,Ticagrelor
,32633174,IC50,Enzyme kinetic study indicated that ticagrelor decreased rivaroxaban metabolic clearance with the IC50 value of 14.04 μmol/L.,Effects of ticagrelor on the pharmacokinetics of rivaroxaban in rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32633174/),[μM] / [l],14.04,172778,DB08816,Ticagrelor
,24444280,bleeding times,Median [range] bleeding times were slightly reduced with ticagrelor plus desmopressin compared with ticagrelor alone (7·50 [3-17] vs. 10·50 [3-25] min at 2·5 h).,The effect of desmopressin on bleeding time and platelet aggregation in healthy volunteers administered ticagrelor. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24444280/),min,7·50,173644,DB08816,Ticagrelor
,24444280,bleeding times,Median [range] bleeding times were slightly reduced with ticagrelor plus desmopressin compared with ticagrelor alone (7·50 [3-17] vs. 10·50 [3-25] min at 2·5 h).,The effect of desmopressin on bleeding time and platelet aggregation in healthy volunteers administered ticagrelor. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24444280/),min,10·50,173645,DB08816,Ticagrelor
,24444280,AUEC,"Co-administration of desmopressin had no impact on IPA, although platelet reactivity was significantly increased (von Willebrand Factor antigen: GLS mean AUEC was 4667%.h for ticagrelor plus desmopressin compared with 2750%.h for ticagrelor alone).",The effect of desmopressin on bleeding time and platelet aggregation in healthy volunteers administered ticagrelor. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24444280/),%·h,4667,173646,DB08816,Ticagrelor
,24444280,AUEC,"Co-administration of desmopressin had no impact on IPA, although platelet reactivity was significantly increased (von Willebrand Factor antigen: GLS mean AUEC was 4667%.h for ticagrelor plus desmopressin compared with 2750%.h for ticagrelor alone).",The effect of desmopressin on bleeding time and platelet aggregation in healthy volunteers administered ticagrelor. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24444280/),%·h,2750,173647,DB08816,Ticagrelor
,29023473,AUC(0-6),"During the first six hours after ticagrelor LD, STEMI patients had 38% and 34% lower plasma concentration of ticagrelor and AR-C124910XX, respectively, than NSTEMI (ticagrelor AUC(0-6): 2491 [344-5587] vs. 3991 [1406-9284] ng*h/mL; p = 0.038; AR-C124910XX AUC(0-6): 473 [0-924] vs. 712 [346-1616] ng*h/mL; p = 0.027).","Comparison of bioavailability and antiplatelet action of ticagrelor in patients with ST-elevation myocardial infarction and non-ST-elevation myocardial infarction: A prospective, observational, single-centre study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29023473/),[h·ng] / [ml],2491,178677,DB08816,Ticagrelor
,29023473,AUC(0-6),"During the first six hours after ticagrelor LD, STEMI patients had 38% and 34% lower plasma concentration of ticagrelor and AR-C124910XX, respectively, than NSTEMI (ticagrelor AUC(0-6): 2491 [344-5587] vs. 3991 [1406-9284] ng*h/mL; p = 0.038; AR-C124910XX AUC(0-6): 473 [0-924] vs. 712 [346-1616] ng*h/mL; p = 0.027).","Comparison of bioavailability and antiplatelet action of ticagrelor in patients with ST-elevation myocardial infarction and non-ST-elevation myocardial infarction: A prospective, observational, single-centre study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29023473/),[h·ng] / [ml],3991,178678,DB08816,Ticagrelor
,29023473,AUC(0-6),"During the first six hours after ticagrelor LD, STEMI patients had 38% and 34% lower plasma concentration of ticagrelor and AR-C124910XX, respectively, than NSTEMI (ticagrelor AUC(0-6): 2491 [344-5587] vs. 3991 [1406-9284] ng*h/mL; p = 0.038; AR-C124910XX AUC(0-6): 473 [0-924] vs. 712 [346-1616] ng*h/mL; p = 0.027).","Comparison of bioavailability and antiplatelet action of ticagrelor in patients with ST-elevation myocardial infarction and non-ST-elevation myocardial infarction: A prospective, observational, single-centre study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29023473/),[h·ng] / [ml],473,178679,DB08816,Ticagrelor
,29023473,AUC(0-6),"During the first six hours after ticagrelor LD, STEMI patients had 38% and 34% lower plasma concentration of ticagrelor and AR-C124910XX, respectively, than NSTEMI (ticagrelor AUC(0-6): 2491 [344-5587] vs. 3991 [1406-9284] ng*h/mL; p = 0.038; AR-C124910XX AUC(0-6): 473 [0-924] vs. 712 [346-1616] ng*h/mL; p = 0.027).","Comparison of bioavailability and antiplatelet action of ticagrelor in patients with ST-elevation myocardial infarction and non-ST-elevation myocardial infarction: A prospective, observational, single-centre study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29023473/),[h·ng] / [ml],712,178680,DB08816,Ticagrelor
,29023473,tmax,STEMI patients also required more time to achieve maximal concentration of ticagrelor (tmax: 4.0 [3.0-12.0] vs. 2.5 [2.0-6.0] h; p = 0.012).,"Comparison of bioavailability and antiplatelet action of ticagrelor in patients with ST-elevation myocardial infarction and non-ST-elevation myocardial infarction: A prospective, observational, single-centre study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29023473/),h,4.0,178681,DB08816,Ticagrelor
,29023473,tmax,STEMI patients also required more time to achieve maximal concentration of ticagrelor (tmax: 4.0 [3.0-12.0] vs. 2.5 [2.0-6.0] h; p = 0.012).,"Comparison of bioavailability and antiplatelet action of ticagrelor in patients with ST-elevation myocardial infarction and non-ST-elevation myocardial infarction: A prospective, observational, single-centre study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29023473/),h,2.5,178682,DB08816,Ticagrelor
,23093043,maximum plasma concentration (Cmax),"Compared with administration of ticagrelor alone, co-administration of ticagrelor and rifampicin significantly decreased the maximum plasma concentration (Cmax) of ticagrelor from 1091 to 297.8 ng/ml, area under the plasma concentration-time curve from time zero to infinity (AUC) of ticagrelor from 6225 to 864.0 ng.h/ml, and also decreased plasma half-life of ticagrelor from 8.4 to 2.8 h; reductions of 73 %, 86 % and 67 % respectively.",Effect of rifampicin on the pharmacokinetics and pharmacodynamics of ticagrelor in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23093043/),[ng] / [ml],109,181360,DB08816,Ticagrelor
,23093043,area under the plasma concentration-time curve from time zero to infinity (AUC),"Compared with administration of ticagrelor alone, co-administration of ticagrelor and rifampicin significantly decreased the maximum plasma concentration (Cmax) of ticagrelor from 1091 to 297.8 ng/ml, area under the plasma concentration-time curve from time zero to infinity (AUC) of ticagrelor from 6225 to 864.0 ng.h/ml, and also decreased plasma half-life of ticagrelor from 8.4 to 2.8 h; reductions of 73 %, 86 % and 67 % respectively.",Effect of rifampicin on the pharmacokinetics and pharmacodynamics of ticagrelor in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23093043/),[h·ng] / [ml],62,181361,DB08816,Ticagrelor
,23093043,plasma half-life,"Compared with administration of ticagrelor alone, co-administration of ticagrelor and rifampicin significantly decreased the maximum plasma concentration (Cmax) of ticagrelor from 1091 to 297.8 ng/ml, area under the plasma concentration-time curve from time zero to infinity (AUC) of ticagrelor from 6225 to 864.0 ng.h/ml, and also decreased plasma half-life of ticagrelor from 8.4 to 2.8 h; reductions of 73 %, 86 % and 67 % respectively.",Effect of rifampicin on the pharmacokinetics and pharmacodynamics of ticagrelor in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23093043/),h,8,181362,DB08816,Ticagrelor
,23093043,plasma half-life,"Compared with administration of ticagrelor alone, co-administration of ticagrelor and rifampicin significantly decreased the maximum plasma concentration (Cmax) of ticagrelor from 1091 to 297.8 ng/ml, area under the plasma concentration-time curve from time zero to infinity (AUC) of ticagrelor from 6225 to 864.0 ng.h/ml, and also decreased plasma half-life of ticagrelor from 8.4 to 2.8 h; reductions of 73 %, 86 % and 67 % respectively.",Effect of rifampicin on the pharmacokinetics and pharmacodynamics of ticagrelor in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23093043/),h,2,181363,DB08816,Ticagrelor
,23748750,maximum plasma concentration,"Co-administration of ticagrelor increased the digoxin maximum plasma concentration by 75 %, from 1.8 ng/ml to 3.0 ng/ml (Gmean ratio [GMR] 1.75 [95 % CI, 1.52-2.01]); minimum plasma concentration by 31 %, from 0.5 ng/ml to 0.7 ng/ml (GMR 1.31, 1.13-1.52); and mean area under the curve by 28 %, from 16.8 ng · h/ml to 21.0 ng · h/ml (GMR 1.28, 1.12-1.46), compared with placebo.",A pharmacokinetic interaction study of ticagrelor and digoxin in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23748750/),[ng] / [ml],1.8,184643,DB08816,Ticagrelor
,23748750,maximum plasma concentration,"Co-administration of ticagrelor increased the digoxin maximum plasma concentration by 75 %, from 1.8 ng/ml to 3.0 ng/ml (Gmean ratio [GMR] 1.75 [95 % CI, 1.52-2.01]); minimum plasma concentration by 31 %, from 0.5 ng/ml to 0.7 ng/ml (GMR 1.31, 1.13-1.52); and mean area under the curve by 28 %, from 16.8 ng · h/ml to 21.0 ng · h/ml (GMR 1.28, 1.12-1.46), compared with placebo.",A pharmacokinetic interaction study of ticagrelor and digoxin in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23748750/),[ng] / [ml],3.0,184644,DB08816,Ticagrelor
,23748750,minimum plasma concentration,"Co-administration of ticagrelor increased the digoxin maximum plasma concentration by 75 %, from 1.8 ng/ml to 3.0 ng/ml (Gmean ratio [GMR] 1.75 [95 % CI, 1.52-2.01]); minimum plasma concentration by 31 %, from 0.5 ng/ml to 0.7 ng/ml (GMR 1.31, 1.13-1.52); and mean area under the curve by 28 %, from 16.8 ng · h/ml to 21.0 ng · h/ml (GMR 1.28, 1.12-1.46), compared with placebo.",A pharmacokinetic interaction study of ticagrelor and digoxin in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23748750/),[ng] / [ml],0.5,184645,DB08816,Ticagrelor
,23748750,minimum plasma concentration,"Co-administration of ticagrelor increased the digoxin maximum plasma concentration by 75 %, from 1.8 ng/ml to 3.0 ng/ml (Gmean ratio [GMR] 1.75 [95 % CI, 1.52-2.01]); minimum plasma concentration by 31 %, from 0.5 ng/ml to 0.7 ng/ml (GMR 1.31, 1.13-1.52); and mean area under the curve by 28 %, from 16.8 ng · h/ml to 21.0 ng · h/ml (GMR 1.28, 1.12-1.46), compared with placebo.",A pharmacokinetic interaction study of ticagrelor and digoxin in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23748750/),[ng] / [ml],0.7,184646,DB08816,Ticagrelor
,23748750,area under the curve,"Co-administration of ticagrelor increased the digoxin maximum plasma concentration by 75 %, from 1.8 ng/ml to 3.0 ng/ml (Gmean ratio [GMR] 1.75 [95 % CI, 1.52-2.01]); minimum plasma concentration by 31 %, from 0.5 ng/ml to 0.7 ng/ml (GMR 1.31, 1.13-1.52); and mean area under the curve by 28 %, from 16.8 ng · h/ml to 21.0 ng · h/ml (GMR 1.28, 1.12-1.46), compared with placebo.",A pharmacokinetic interaction study of ticagrelor and digoxin in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23748750/),[h·ng] / [ml],16.8,184647,DB08816,Ticagrelor
,23748750,area under the curve,"Co-administration of ticagrelor increased the digoxin maximum plasma concentration by 75 %, from 1.8 ng/ml to 3.0 ng/ml (Gmean ratio [GMR] 1.75 [95 % CI, 1.52-2.01]); minimum plasma concentration by 31 %, from 0.5 ng/ml to 0.7 ng/ml (GMR 1.31, 1.13-1.52); and mean area under the curve by 28 %, from 16.8 ng · h/ml to 21.0 ng · h/ml (GMR 1.28, 1.12-1.46), compared with placebo.",A pharmacokinetic interaction study of ticagrelor and digoxin in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23748750/),[h·ng] / [ml],21.0,184648,DB08816,Ticagrelor
,30675914,flow rate,Acetonitrile and 5 mΜ ammonium acetate was used as the mobile phase with a gradient elution at a flow rate of 0.5 mL/min.,Validated liquid chromatography-tandem mass spectrometry method for quantification of ticagrelor and its active metabolite in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30675914/),[ml] / [min],0.5,188670,DB08816,Ticagrelor
,34114623,trough levels,There were no significant differences in the primary endpoint (trough levels of VASP-PRI following ticagrelor 90 mg dosing) between cohorts (31 ± 20 vs 25 ± 14; p = 0.105).,Impact Of Chronic Kidney Disease On The Pharmacodynamic And Pharmacokinetic Effects Of Ticagrelor In Patients With Diabetes Mellitus And Coronary Artery Disease. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34114623/),,31,195243,DB08816,Ticagrelor
,34114623,trough levels,There were no significant differences in the primary endpoint (trough levels of VASP-PRI following ticagrelor 90 mg dosing) between cohorts (31 ± 20 vs 25 ± 14; p = 0.105).,Impact Of Chronic Kidney Disease On The Pharmacodynamic And Pharmacokinetic Effects Of Ticagrelor In Patients With Diabetes Mellitus And Coronary Artery Disease. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34114623/),,25,195244,DB08816,Ticagrelor
,27165805,matrix effects,The matrix effects of plasma and urine were in the range of 98.3-110.7% for ticagrelor and 102.1-112.3% for M8.,Simultaneous Determination of Ticagrelor and Its Metabolites in Human Plasma and Urine Using Liquid Chromatography-Tandem Mass Spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27165805/),,98.3-110.7,198289,DB08816,Ticagrelor
,27165805,matrix effects,The matrix effects of plasma and urine were in the range of 98.3-110.7% for ticagrelor and 102.1-112.3% for M8.,Simultaneous Determination of Ticagrelor and Its Metabolites in Human Plasma and Urine Using Liquid Chromatography-Tandem Mass Spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27165805/),,102.1-112.3,198290,DB08816,Ticagrelor
,32055590,m,"Mass spectrometric detection and quantitation were conducted by selected reaction-monitoring on a negative electrospray ionization mode with the following transitions: m/z 521.11 → 361.10, 477.03 → 361.10, and 269.00 → 169.60 for ticagrelor, AR-C124910XX, and tolbutamide, respectively.","Simultaneous quantification of ticagrelor and its active metabolite, AR-C124910XX, in human plasma by liquid chromatography-tandem mass spectrometry: Applications in steady-state pharmacokinetics in patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32055590/),,521.11,203077,DB08816,Ticagrelor
,32055590,m,"Mass spectrometric detection and quantitation were conducted by selected reaction-monitoring on a negative electrospray ionization mode with the following transitions: m/z 521.11 → 361.10, 477.03 → 361.10, and 269.00 → 169.60 for ticagrelor, AR-C124910XX, and tolbutamide, respectively.","Simultaneous quantification of ticagrelor and its active metabolite, AR-C124910XX, in human plasma by liquid chromatography-tandem mass spectrometry: Applications in steady-state pharmacokinetics in patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32055590/),,477.03,203078,DB08816,Ticagrelor
,32055590,m,"Mass spectrometric detection and quantitation were conducted by selected reaction-monitoring on a negative electrospray ionization mode with the following transitions: m/z 521.11 → 361.10, 477.03 → 361.10, and 269.00 → 169.60 for ticagrelor, AR-C124910XX, and tolbutamide, respectively.","Simultaneous quantification of ticagrelor and its active metabolite, AR-C124910XX, in human plasma by liquid chromatography-tandem mass spectrometry: Applications in steady-state pharmacokinetics in patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32055590/),,269.00,203079,DB08816,Ticagrelor
,26491112,AUC(0-12),"Morphine lowered the total exposure to ticagrelor and its active metabolite by 36% (AUC(0-12): 6307 vs. 9791 ng h/mL; P = 0.003), and 37% (AUC(0-12): 1503 vs. 2388 ng h/mL; P = 0.008), respectively, with a concomitant delay in maximal plasma concentration of ticagrelor (4 vs. 2 h; P = 0.004).","Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26491112/),[h·ng] / [ml],6307,206850,DB08816,Ticagrelor
,26491112,AUC(0-12),"Morphine lowered the total exposure to ticagrelor and its active metabolite by 36% (AUC(0-12): 6307 vs. 9791 ng h/mL; P = 0.003), and 37% (AUC(0-12): 1503 vs. 2388 ng h/mL; P = 0.008), respectively, with a concomitant delay in maximal plasma concentration of ticagrelor (4 vs. 2 h; P = 0.004).","Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26491112/),[h·ng] / [ml],9791,206851,DB08816,Ticagrelor
,26491112,AUC(0-12),"Morphine lowered the total exposure to ticagrelor and its active metabolite by 36% (AUC(0-12): 6307 vs. 9791 ng h/mL; P = 0.003), and 37% (AUC(0-12): 1503 vs. 2388 ng h/mL; P = 0.008), respectively, with a concomitant delay in maximal plasma concentration of ticagrelor (4 vs. 2 h; P = 0.004).","Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26491112/),[h·ng] / [ml],1503,206852,DB08816,Ticagrelor
,26491112,AUC(0-12),"Morphine lowered the total exposure to ticagrelor and its active metabolite by 36% (AUC(0-12): 6307 vs. 9791 ng h/mL; P = 0.003), and 37% (AUC(0-12): 1503 vs. 2388 ng h/mL; P = 0.008), respectively, with a concomitant delay in maximal plasma concentration of ticagrelor (4 vs. 2 h; P = 0.004).","Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26491112/),[h·ng] / [ml],2388,206853,DB08816,Ticagrelor
,26491112,maximal plasma concentration,"Morphine lowered the total exposure to ticagrelor and its active metabolite by 36% (AUC(0-12): 6307 vs. 9791 ng h/mL; P = 0.003), and 37% (AUC(0-12): 1503 vs. 2388 ng h/mL; P = 0.008), respectively, with a concomitant delay in maximal plasma concentration of ticagrelor (4 vs. 2 h; P = 0.004).","Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26491112/),h,4,206854,DB08816,Ticagrelor
,26491112,maximal plasma concentration,"Morphine lowered the total exposure to ticagrelor and its active metabolite by 36% (AUC(0-12): 6307 vs. 9791 ng h/mL; P = 0.003), and 37% (AUC(0-12): 1503 vs. 2388 ng h/mL; P = 0.008), respectively, with a concomitant delay in maximal plasma concentration of ticagrelor (4 vs. 2 h; P = 0.004).","Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26491112/),h,2,206855,DB08816,Ticagrelor
,25500486,plasma,"At 0.5 hours postdose, plasma concentrations of ticagrelor and AR-C124910XX were higher with crushed tablets administered orally (148.6 ng/mL and 13.0 ng/mL, respectively) or via nasogastric tube (264.6 ng/mL and 28.6 ng/mL, respectively) compared with whole-tablet administration (33.3 ng/mL and 5.2 ng/mL, respectively).","An open-label, randomized bioavailability study with alternative methods of administration of crushed ticagrelor tablets in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25500486/),[ng] / [ml],148.6,211238,DB08816,Ticagrelor
,25500486,plasma,"At 0.5 hours postdose, plasma concentrations of ticagrelor and AR-C124910XX were higher with crushed tablets administered orally (148.6 ng/mL and 13.0 ng/mL, respectively) or via nasogastric tube (264.6 ng/mL and 28.6 ng/mL, respectively) compared with whole-tablet administration (33.3 ng/mL and 5.2 ng/mL, respectively).","An open-label, randomized bioavailability study with alternative methods of administration of crushed ticagrelor tablets in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25500486/),[ng] / [ml],264.6,211239,DB08816,Ticagrelor
,25500486,plasma,"At 0.5 hours postdose, plasma concentrations of ticagrelor and AR-C124910XX were higher with crushed tablets administered orally (148.6 ng/mL and 13.0 ng/mL, respectively) or via nasogastric tube (264.6 ng/mL and 28.6 ng/mL, respectively) compared with whole-tablet administration (33.3 ng/mL and 5.2 ng/mL, respectively).","An open-label, randomized bioavailability study with alternative methods of administration of crushed ticagrelor tablets in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25500486/),[ng] / [ml],28.6,211240,DB08816,Ticagrelor
,25500486,plasma,"At 0.5 hours postdose, plasma concentrations of ticagrelor and AR-C124910XX were higher with crushed tablets administered orally (148.6 ng/mL and 13.0 ng/mL, respectively) or via nasogastric tube (264.6 ng/mL and 28.6 ng/mL, respectively) compared with whole-tablet administration (33.3 ng/mL and 5.2 ng/mL, respectively).","An open-label, randomized bioavailability study with alternative methods of administration of crushed ticagrelor tablets in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25500486/),[ng] / [ml],33.3,211241,DB08816,Ticagrelor
,25500486,plasma,"At 0.5 hours postdose, plasma concentrations of ticagrelor and AR-C124910XX were higher with crushed tablets administered orally (148.6 ng/mL and 13.0 ng/mL, respectively) or via nasogastric tube (264.6 ng/mL and 28.6 ng/mL, respectively) compared with whole-tablet administration (33.3 ng/mL and 5.2 ng/mL, respectively).","An open-label, randomized bioavailability study with alternative methods of administration of crushed ticagrelor tablets in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25500486/),[ng] / [ml],5.2,211242,DB08816,Ticagrelor
,25500486,tmax,"Ticagrelor tmax was shorter following crushed vs. whole-tablet administration (1 vs. 2 hours, respectively).","An open-label, randomized bioavailability study with alternative methods of administration of crushed ticagrelor tablets in healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25500486/),h,1,211243,DB08816,Ticagrelor
,25500486,tmax,"Ticagrelor tmax was shorter following crushed vs. whole-tablet administration (1 vs. 2 hours, respectively).","An open-label, randomized bioavailability study with alternative methods of administration of crushed ticagrelor tablets in healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25500486/),h,2,211244,DB08816,Ticagrelor
,22168538,time [t(max)] to reach maximum plasma concentration [C(max)],"Following single and multiple doses at both dose levels, ticagrelor was rapidly absorbed (median time [t(max)] to reach maximum plasma concentration [C(max)] 2 hours) with a mean elimination half-life (t(1/2;)) of 10.9-14.9 hours.","Pharmacokinetics and tolerability of single and multiple doses of ticagrelor in healthy Chinese subjects: an open-label, sequential, two-cohort, single-centre study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22168538/),h,2,222637,DB08816,Ticagrelor
,22168538,elimination half-life (t(1/2;)),"Following single and multiple doses at both dose levels, ticagrelor was rapidly absorbed (median time [t(max)] to reach maximum plasma concentration [C(max)] 2 hours) with a mean elimination half-life (t(1/2;)) of 10.9-14.9 hours.","Pharmacokinetics and tolerability of single and multiple doses of ticagrelor in healthy Chinese subjects: an open-label, sequential, two-cohort, single-centre study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22168538/),h,10.9-14.9,222638,DB08816,Ticagrelor
,22168538,t(max),AR-C124910XX was rapidly formed (median t(max) 2.0-3.0 hours; mean t(1/2;) 9.1-11.9 hours).,"Pharmacokinetics and tolerability of single and multiple doses of ticagrelor in healthy Chinese subjects: an open-label, sequential, two-cohort, single-centre study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22168538/),h,2.0-3.0,222639,DB08816,Ticagrelor
,22168538,t(1/2;),AR-C124910XX was rapidly formed (median t(max) 2.0-3.0 hours; mean t(1/2;) 9.1-11.9 hours).,"Pharmacokinetics and tolerability of single and multiple doses of ticagrelor in healthy Chinese subjects: an open-label, sequential, two-cohort, single-centre study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22168538/),h,9.1-11.9,222640,DB08816,Ticagrelor
,22168538,C(max),"Both parent and metabolite exhibited linear and predictable pharmacokinetics with single and multiple dosing as mean minimum plasma concentration (C(min)), C(max) and area under the plasma concentration-time curve from time zero to infinity (AUC(∞)) were approximately 2-fold higher with ticagrelor 180 mg (e.g. multiple-dosing, geometric mean [% coefficient of variation]: C(max) 1973 [27] and AUC(∞) 18 035 [46]) versus 90 mg (e.g. multiple dosing: C(max) 915 [32] and AUC(∞) 7168 [35]) dosing regimens.","Pharmacokinetics and tolerability of single and multiple doses of ticagrelor in healthy Chinese subjects: an open-label, sequential, two-cohort, single-centre study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22168538/),,1973,222641,DB08816,Ticagrelor
,22168538,AUC(∞),"Both parent and metabolite exhibited linear and predictable pharmacokinetics with single and multiple dosing as mean minimum plasma concentration (C(min)), C(max) and area under the plasma concentration-time curve from time zero to infinity (AUC(∞)) were approximately 2-fold higher with ticagrelor 180 mg (e.g. multiple-dosing, geometric mean [% coefficient of variation]: C(max) 1973 [27] and AUC(∞) 18 035 [46]) versus 90 mg (e.g. multiple dosing: C(max) 915 [32] and AUC(∞) 7168 [35]) dosing regimens.","Pharmacokinetics and tolerability of single and multiple doses of ticagrelor in healthy Chinese subjects: an open-label, sequential, two-cohort, single-centre study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22168538/),,18 035,222642,DB08816,Ticagrelor
,22168538,C(max),"Both parent and metabolite exhibited linear and predictable pharmacokinetics with single and multiple dosing as mean minimum plasma concentration (C(min)), C(max) and area under the plasma concentration-time curve from time zero to infinity (AUC(∞)) were approximately 2-fold higher with ticagrelor 180 mg (e.g. multiple-dosing, geometric mean [% coefficient of variation]: C(max) 1973 [27] and AUC(∞) 18 035 [46]) versus 90 mg (e.g. multiple dosing: C(max) 915 [32] and AUC(∞) 7168 [35]) dosing regimens.","Pharmacokinetics and tolerability of single and multiple doses of ticagrelor in healthy Chinese subjects: an open-label, sequential, two-cohort, single-centre study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22168538/),,915,222643,DB08816,Ticagrelor
,22168538,AUC(∞),"Both parent and metabolite exhibited linear and predictable pharmacokinetics with single and multiple dosing as mean minimum plasma concentration (C(min)), C(max) and area under the plasma concentration-time curve from time zero to infinity (AUC(∞)) were approximately 2-fold higher with ticagrelor 180 mg (e.g. multiple-dosing, geometric mean [% coefficient of variation]: C(max) 1973 [27] and AUC(∞) 18 035 [46]) versus 90 mg (e.g. multiple dosing: C(max) 915 [32] and AUC(∞) 7168 [35]) dosing regimens.","Pharmacokinetics and tolerability of single and multiple doses of ticagrelor in healthy Chinese subjects: an open-label, sequential, two-cohort, single-centre study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22168538/),,7168,222644,DB08816,Ticagrelor
,20551239,half-life,"In most subjects, radioactivity was undetectable in plasma after 20 h and whole blood after 12 h (half-life values of 6.3 and 4.6 h, respectively).","Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20551239/),h,6.3,225044,DB08816,Ticagrelor
,20551239,half-life,"In most subjects, radioactivity was undetectable in plasma after 20 h and whole blood after 12 h (half-life values of 6.3 and 4.6 h, respectively).","Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20551239/),h,4.6,225045,DB08816,Ticagrelor
,20551239,ratio of radioactivity,"The ratio of radioactivity in plasma to whole blood was 1.69, suggesting that ticagrelor and its metabolites are largely restricted to the plasma space.","Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20551239/),,1.69,225046,DB08816,Ticagrelor
,20551239,radioactivity recovery,Mean radioactivity recovery was 26.5% in urine and 57.8% in feces.,"Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20551239/),%,26.5,225047,DB08816,Ticagrelor
,20551239,radioactivity recovery,Mean radioactivity recovery was 26.5% in urine and 57.8% in feces.,"Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20551239/),%,57.8,225048,DB08816,Ticagrelor
,30863054,area under the inhibitory curve,"And, a 10 mg/kg dose of raw TCG suspension and a 5 mg/kg dose of TCG-SM had a similar area under the inhibitory curve (907.0%±408.8% and 907.8%±200.5%⋅hours, respectively) for antiplatelet activity.",Strategic approach to developing a self-microemulsifying drug delivery system to enhance antiplatelet activity and bioavailability of ticagrelor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30863054/),%,907.0,242418,DB08816,Ticagrelor
,30863054,area under the inhibitory curve,"And, a 10 mg/kg dose of raw TCG suspension and a 5 mg/kg dose of TCG-SM had a similar area under the inhibitory curve (907.0%±408.8% and 907.8%±200.5%⋅hours, respectively) for antiplatelet activity.",Strategic approach to developing a self-microemulsifying drug delivery system to enhance antiplatelet activity and bioavailability of ticagrelor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30863054/),%,907.8,242419,DB08816,Ticagrelor
,22190065,excretion,Urinary uric acid excretion was significantly higher on day 1 (7%) and at 24-48 h after the morning dose on day 5 (17%) relative to placebo.,Evaluation and characterization of the effects of ticagrelor on serum and urinary uric acid in healthy volunteers. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22190065/),,7,248109,DB08816,Ticagrelor
,22515556,maximum (peak) plasma concentration (C(max)),"In ONSET-OFFSET, maximum (peak) plasma concentration (C(max)), time to C(max) (t(max)) and area under the plasma concentration-time curve from time 0 to 8 hours (AUC(8)) for ticagrelor were 733 ng/mL, 2.0 hours and 4130 ng · h/mL, respectively; and for AR-C124910XX were 210 ng/mL, 2.1 hours and 1325 ng · h/mL, respectively.",Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22515556/),[ng] / [ml],733,250416,DB08816,Ticagrelor
,22515556,time to C(max) (t(max)),"In ONSET-OFFSET, maximum (peak) plasma concentration (C(max)), time to C(max) (t(max)) and area under the plasma concentration-time curve from time 0 to 8 hours (AUC(8)) for ticagrelor were 733 ng/mL, 2.0 hours and 4130 ng · h/mL, respectively; and for AR-C124910XX were 210 ng/mL, 2.1 hours and 1325 ng · h/mL, respectively.",Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22515556/),h,2.0,250417,DB08816,Ticagrelor
,22515556,time to C(max) (t(max)),"In ONSET-OFFSET, maximum (peak) plasma concentration (C(max)), time to C(max) (t(max)) and area under the plasma concentration-time curve from time 0 to 8 hours (AUC(8)) for ticagrelor were 733 ng/mL, 2.0 hours and 4130 ng · h/mL, respectively; and for AR-C124910XX were 210 ng/mL, 2.1 hours and 1325 ng · h/mL, respectively.",Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22515556/),[ng] / [ml],210,250418,DB08816,Ticagrelor
,22515556,time to C(max) (t(max)),"In ONSET-OFFSET, maximum (peak) plasma concentration (C(max)), time to C(max) (t(max)) and area under the plasma concentration-time curve from time 0 to 8 hours (AUC(8)) for ticagrelor were 733 ng/mL, 2.0 hours and 4130 ng · h/mL, respectively; and for AR-C124910XX were 210 ng/mL, 2.1 hours and 1325 ng · h/mL, respectively.",Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22515556/),h,2.1,250419,DB08816,Ticagrelor
,22515556,area under the plasma concentration-time curve from time 0 to 8 hours (AUC(8)),"In ONSET-OFFSET, maximum (peak) plasma concentration (C(max)), time to C(max) (t(max)) and area under the plasma concentration-time curve from time 0 to 8 hours (AUC(8)) for ticagrelor were 733 ng/mL, 2.0 hours and 4130 ng · h/mL, respectively; and for AR-C124910XX were 210 ng/mL, 2.1 hours and 1325 ng · h/mL, respectively.",Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22515556/),[h·ng] / [ml],4130,250420,DB08816,Ticagrelor
,22515556,area under the plasma concentration-time curve from time 0 to 8 hours (AUC(8)),"In ONSET-OFFSET, maximum (peak) plasma concentration (C(max)), time to C(max) (t(max)) and area under the plasma concentration-time curve from time 0 to 8 hours (AUC(8)) for ticagrelor were 733 ng/mL, 2.0 hours and 4130 ng · h/mL, respectively; and for AR-C124910XX were 210 ng/mL, 2.1 hours and 1325 ng · h/mL, respectively.",Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22515556/),[h·ng] / [ml],1325,250421,DB08816,Ticagrelor
,22515556,Trough plasma ticagrelor,Trough plasma ticagrelor (305 ng/mL) and AR-C124910XX (121 ng/mL) concentrations were 5.2 and 7.7 times higher than respective concentration producing 50% of maximum effect (EC(50)) estimates.,Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22515556/),[ng] / [ml],305,250422,DB08816,Ticagrelor
,22515556,Trough plasma ticagrelor,Trough plasma ticagrelor (305 ng/mL) and AR-C124910XX (121 ng/mL) concentrations were 5.2 and 7.7 times higher than respective concentration producing 50% of maximum effect (EC(50)) estimates.,Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22515556/),[ng] / [ml],121,250423,DB08816,Ticagrelor
,22515556,C(max),"In RESPOND, ticagrelor mean C(max) and AUC(8) following 2-week dosing were comparable between clopidogrel responders (724 ng/mL and 3983 ng · h/mL, respectively) and non-responders (764 ng/mL and 3986 ng · h/mL, respectively).",Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22515556/),[ng] / [ml],724,250424,DB08816,Ticagrelor
,22515556,C(max),"In RESPOND, ticagrelor mean C(max) and AUC(8) following 2-week dosing were comparable between clopidogrel responders (724 ng/mL and 3983 ng · h/mL, respectively) and non-responders (764 ng/mL and 3986 ng · h/mL, respectively).",Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22515556/),[ng] / [ml],764,250425,DB08816,Ticagrelor
,22515556,AUC(8),"In RESPOND, ticagrelor mean C(max) and AUC(8) following 2-week dosing were comparable between clopidogrel responders (724 ng/mL and 3983 ng · h/mL, respectively) and non-responders (764 ng/mL and 3986 ng · h/mL, respectively).",Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22515556/),[h·ng] / [ml],3983,250426,DB08816,Ticagrelor
,22515556,AUC(8),"In RESPOND, ticagrelor mean C(max) and AUC(8) following 2-week dosing were comparable between clopidogrel responders (724 ng/mL and 3983 ng · h/mL, respectively) and non-responders (764 ng/mL and 3986 ng · h/mL, respectively).",Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22515556/),[h·ng] / [ml],3986,250427,DB08816,Ticagrelor
